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AIMS AND OBJECTIVES
(i) Determine the prevalence and significance of MEFV mutations and 
Factor V Leiden mutation among  Palestinian patients with Behçet’s 
disease.
(ii) Assess the MEFV mutations profile in Palestinian Behçet’s disease 
patients.
(iii) Determine whether the clinical severity of Behçet’s disease phenotype 
correlates with the nature of MEFV mutation.
(iv) Evaluate the significance of MEFV gene analysis for Behçet’s disease 
diagnosis.
xiv
ABSTRACT
Keywords: Behçet's disease,  Familial Mediterranean fever, MEFV, Pyrin,
                     Factor V Leiden.
Behçet's disease (BD) and familial Mediterranean fever (FMF), both 
inflammatory diseases, are highly prevalent in the Middle Eastern and 
Mediterranean populations. BD is a multisystemic disorder with major 
manifestations of recurrent orogenital ulcerations, skin lesions, and uveitis, 
in which vasculitis plays an important pathogenic role. BD is a polyfactorial 
disease closely associated with HLA-B51. On the other hand, FMF is 
characterized by recurrent, short, self-limited episodes of fever, serosal 
inflammation manifested mainly by sterile peritonitis, pleurisy, and 
arthritis, and gradual development of nephropathic amyloidosis. FMF is an 
autosomal recessive disease linked to a gene located on the short arm of 
chromosome 16, designated "MEFV". It encodes a novel protein called 
"pyrin" or "marenostrin" that is expressed predominantly in neutrophils and 
monocytes and believed to play a role in inflammation and apoptosis.
Considering the phenotypic and epidemiological similarities between 
FMF and BD, the inflammatory reactions that underlie the genesis of both 
diseases,  and  that  factor  V  Leiden  mutation  may  play  a  role  in  the 
hypercoagulable  state  in  BD,  we identified  MEFV and factor  V Leiden 
mutations in 44 Palestinian patients with Behçet's disease who did not meet 
the  clinical  criteria  for  FMF.  We  screened  for  34  MEFV mutations,  9 
MEFV polymorphisms, and factor V Leiden mutation in 88 chromosomes 
from 28 definite BD patients (meeting the criteria of the International Study 
Group for  BD),  12 probable BD patients  (meeting at  least  two of  these 
criteria),  and  4  suspected  BD  patients  (meeting  at  least  one  of  these 
criteria).
Four patients carried two mutated MEFV alleles, and fourteen had one 
mutated MEFV allele. Altogether, 22 of the 88 chromosomes studied bore 
MEFV mutations/polymorphisms. Furthermore, 18 BD patients (40.9%) 
xv
had nine different MEFV mutations and two polymorphisms, which 
represents the sensitivity of testing these mutations in our samples. V726A, 
M694V, M694I, and E148Q mutations and P706 polymorphism have been 
previously described in BD patients, whereas F479L, P369S, R408Q, and 
A744S mutations and F721 polymorphism are reported in BD patients for 
the first time in this study. Interestingly, we identified a novel MEFV 
mutation that have not been reported before in either FMF or BD patients. 
This mutation encodes a substitution of methionine for valine at position 
722 (V722M). In addition, factor V Leiden mutation was detected in only 
five of the forty four (11.4%) studied BD patients. 
This  study is  the  first  genetic  analysis  of  the  MEFV and factor  V 
Leiden mutations among Palestinian BD patients. It reflects the mutations 
profile  in  our  BD patients.  Our  results  were  in  concordance  with  other 
studies  in  providing  further  data  that  MEFV  gene  mutations  are  an 
additional  genetic  susceptibility  factor  in  BD,  and therefore,  the  genetic 
testing for MEFV mutations may be advisable in the investigation of BD 
among patients  of  Mediterranean origin.  The population  comprising this 
study  may  not  be  enough  to  role  out  the  correlation  between  MEFV 
mutations and the clinical manifestations of BD on one hand, and factor V 
Leiden and venous thrombosis on the other hand. Therefore, studies in large 
number of BD series are needed.
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الملخص
 يعتبر كل من مرض البهجت و حمى البحر البيض المتوسط العائلية من المراض المنتشششرة
 في منطقة حوض البحر البيض المتوسط. مرض البهجت هو التهاب أوعيشة معمشم يتميشز بتقرحشات
 فموية متكررة، وتقرحات تناسشلية، وآفشات جلديشة، وإصشابة عينيشة، بالضشافة إلشى إصشابة مفصشلية
 وعصبية وهضمية. بينما حمى البحر البيض المتوسشط العائليشة هشي مشرض وراثشي يتميشز بنوبشات
 متكررة من ارتفاع درجة حرارة الجسشم مصشاحبة للم بشالبطن والصشدر والمفاصشل نتيجشة التهشاب
 الغشية المغلفة لها. أهم مشاكل هذا المرض التي تظهر نتيجة لعدم العلج هشو الترسشيب الشبروتيني
 م توصل الباحثون إلى معرفة الجيشن المرتبشط بحمشى البحشر البيشض7991)أميلويدوزيز(. في عام 
 ". هذا الجيششنVFEM والذي أطلق عليه اسم "61المتوسط العائلية الموجود على الكروموسوم رقم 
 ينتج بروتين يدعى "بايرين" يلعب دورا في تقليل حدة اللتهاب، إذا حدثت طفرة في هذا الجيشن فشإن
حدة اللتهاب ل تكون منضبطة بشكل طبيعي مما يسبب نوبات الحمى للمرض.
 نظرا للتشابه القائم بين مرض البهجت وحمى البحر البيض المتوسشط العائليشة فشي الظشواهر
 الكلينيكية والتوزيع الجغرافي، إلى جانب دور بروتين البايرين في التفشاعلت اللتهابيشة، بالضشافة
 إلى أن طفرة ليدن العامل الخامس وجد بأنها تلعب دورا فشي حالشة التخشثر الشزائدة الشتي تظهشر فشي
  مريشض فلسشطيني44 وطفشرة ليشدن فشي VFEMمرض البهجت، قمنا بفحص كل من طفرات ال
 مصابين بمرض البهجت. يجب الشارة هنا إلى أن هؤلء المرضى والشتي ششملتهم هشذه الدراسشة ل
 تنطبق عليهم المعايير الكلينيكية الخاصة بتشخيص مرض حمى البحشر البيشض المتوسشط العائليشة.
  مشن المتعشددات الششكلية فشي جيشن ال9 وVFEM طفشرة  43في هذا البحث قمنشا بمسشح جينشي ل 
  مريشض مؤكشد أنهشم مصشابين بمشرض البهجشت82 كروموسوما من 88 و طفرة ليدن ل VFEM
  مريشض محتمشل أنهشم21)تنطبشق عليهشم معشايير مجموعشة الدراسشة العالميشة لمشرض البهجشت(، و 
  مرضشى متوقشع4مصابين بمرض البهجت )ينطبق عليهم على القل معيارين من هذه المعشايير(، و 
أنهم يعانون من مرض البهجت )ينطبق عليهم معيار واحد من هذه المعايير(.
  التي تمت دراستها احتوت على88 كروموسوما من أصل ال22بعد التحليل الجيني وجد أن 
  مرضشى حملشوا كروموسشومين ذي صشفة طفريشة4  .VFEMطفرات أو متعددات شكلية لجيشن ال 
  طفشرات9 مريضا آخرين حملوا كروموسوما واحدا ذي صشفة طفريشة. علوة علشى ذلشك، 41بينما 
  % مشن مرضشى9.04 تشم تشخيصشها فشي VFEMمختلفة واثنتان من المتعددات الششكلية لجيشن ال 
  فشي المرضشى الفلسشطينيين الشذينVFEMالبهجت، هذه النتيجة تمثشل حساسشية فحشص طفشرات ال 
 يعانون من مشرض البهجشت. عشدد مشن الطفشرات والمتعشددات الششكلية الشتي تشم تشخيصشها فشي هشذه
  وV496Mو A627V الدراسشة قشد تشم وصشفها فشي مرضشى البهجشت فشي دراسشات سشابقة مثشل: 
  وQ804R و S963P و L974F  . بينمششششا عششششددا آخششششر مثششششل:607P و Q841Eو  I496M
  تشم تسشجيلها فشي مرضشى البهجشت للمشرة الولشى فشي هشذا البحشث. مشن الجشدير127FوS447A
  جديدة تمثل استبدال الحامض الميني من مشثيونين إلشىVFEMبالهتمام، أنه تم الكشف عن طفرة 
iivx
 (، هذه الطفرة لم يتم تسشجيلها مسشبقا فشي كشل مشن مرضشىM227V  )227فالين على كودون رقم 
 حمى البحر البيض المتوسط أو مرضى البهجت. أضف إلى ذلك، أنه تم تشخيص طفشرة ليشدن فشي
 مريضا الذين شملتهم هذه الدراسة.44%( من أصل ال4.11خمسة مرضى فقط )
   وطفشرة ليشدن بيشن المرضشىVFEMتعتبر هذه الدراسة التحليل الجيني الول لطفرات ال 
 الفلسطينيين المصابين بمرض البهجت, بالضافة إلى أنها تعكس صورة هذه الطفرات فششي مرضششانا
 من ناحية أخرى. نتائج هذه الدراسة تتفق مع نتائج الدراسات الخرى بكونها تزود معطيات إضششافية
  هي عبارة عن عامل جيني إضافي مؤثر في مشرض البهجشت، ولشذلك، فشإنVFEMأن طفرات ال 
  يمكن أن يكون ملئمشا لفحشص مرضشى البهجشت الشذين تنحشدرVFEMالتحليل الجيني لطفرات ال 
 أصولهم من منطقة البحر البيض المتوسط. قد يكون عدد المرضى الذين شملتهم هذه الدراسشة غيشر
  وبين الظواهر الكلينيكية لمرض البهجت مششن جهششة،VFEMكاف لستبعاد الصلة بين طفرات ال 
 والصلة بين طفرة ليدن وبين حالة التجلط في هذا المرض من جهة أخرى. ولذلك، تقتضشي الحاجشة
إلى دراسات على عدد أكبر من مرضى البهجت.
iiivx
CHAPTER I
INTRODUCTION
1
CHAPTER I
INTRODUCTION
I.1 BEHÇET'S DISEASE
Behçet’s  disease  (BD)  is  a  multisystemic  inflammatory  disease 
characterized by recurrent oral and genital ulcers, uveitis and skin lesions, 
as  well  as  articular,  vascular,  neurological,  intestinal  and  pulmonary 
manifestations [Sakane et al., 1999].
I.1.1 Historical Background
One of the earliest descriptions of an illness, which bears similarities 
to  BD, is found in Hippocrates writing in 450 B.C. from ancient Greece. 
Many of the features described are recognized in the various disease criteria 
in use today:
“But there were also other fevers – Many had their mouth affected  
with  aphthous  ulcerations.  There  were  also  many  defluxions  about  the 
genital  parts,  and ulcerations,  boils  externally and internally,  about the 
groins.  Watery  ophthalmies  of  chronic  character,  with  pains;  fungous 
excretions  of  the  eyelids,  externally  and  internally,  called  fici,  which  
destroyed the sight of many persons. There were also attacks of carbuncle  
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through the summer – and large ecthymata and herpetes (rash) in many  
instances” [Verity et al., 1999a].
An earlier reference to this collection of clinical signs is reported from 
the writings of the Chinese physician Zhong-Jing Zhang in about 200 A.D., 
but no further description is encountered in the medical literature for 1,700 
years.  Not  until  the  early  of  1900s,  were  individual  features  such  as 
recurrent relapsing hypopyon uveitis, oral aphthae and combined orogenital 
ulcerations were described by Blüthe in 1908, Planner and Remenovsky in 
1922, Shigeta in Japan in 1924, Gilbert in 1925, Dascalopoulos in 1932, 
and  Whitwell  in  Great  Britain  in  1934  [Verity  et  al.,  1999a;  McCarty, 
1989].
Behçet’s  disease owes  its  name to  the  Turkish  physician  professor 
Hûlusi Behçet, who, in 1937, described the classic trisymptom complex of 
hypopyon, iritis, and orogenital aphthosis [Behçet, 1937]. Behçet first saw a 
patient in 1924/25 who had oral and genital aphthae, eye involvement, and 
nodular  lesions  in  his  legs.  Syphilis,  tuberculosis,  staphylococci,  or 
streptococci  were  interpreted  in  the  etiology  by  ophthalmologists  who 
followed the relapsing and remitting uveitis. The patient, who underwent 
several iridectomies, completely lost his vision. The other attacks continued 
with  wider  intervals.  Behçet  closely  followed  this  patient  and  carefully 
evaluated his attacks. The second patient was a woman who emerged in 
1930s  with  several-year  history  of  oral  aphthae,  genital  ulcers,  and 
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hemorrhage  in  the  eye.  Syphilis,  tuberculosis,  and  fungal  tests  were 
performed in addition to biopsies and laboratory examinations. The results 
were  not  compatible  with  a  known  disease.  A  male  patient  who  had 
pemphigus-like lesions in his mouth was referred in 1936 from a dental 
clinic.  He  had  acneiform  lesions  in  the  back,  ulcers  in  the  scrotum, 
hemorrhage and loss of vision in the eye, and fevers and myalgias were 
observed mainly  at  night.  Behçet  proposed  that  these  signs  belong to  a 
specific  disease  entity  and  suggested  a  virus  as  a  causative  agent. 
Eventually, in 1947, he gained widespread international recognition for this 
finding  [Saylan  et  al.,  1999].  The  Greek  physician  Benediktos 
Adamantiades reported the disease in 1931, accounting for the alternative 
eponym  Adamantiades-Behçet  disease [Adamantiades,  1931]. 
Adamantiades defined thrombophlebitis as the fourth cardinal sign of the 
disease  and  pointed  out  that  the  disease  can  occur  for  years  as  a 
monosymptomatic disorder and that eye involvement and severe prognosis 
are  more  common  in  men  than  in  women [Zouboulis  and  Kaklamanis, 
2003]. 
I.1.2 Epidemiology
Cases of BD cluster in countries spanning the Mediterranean basin and 
the Far East. This led to the synonym of Silk Road disease. These regions 
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lie between latitudes 30º and 45º north. One attractive hypothesis is that BD 
spread through Asian and Eurasian populations from Japan to the Middle 
East, together with its associated HLA allele, HLA-B51, as a result of the 
movement of nomadic or Turkish tribes traveling the ancient trading Silk 
Route [Verity et al., 1999a]. 
The prevalence of  BD varies in different parts of the world. Turkey 
has the highest prevalence, where two epidemiological studies were done. 
A prevalence of 80 per 100,000 populations were reported in nine villages 
near  Istanbul  [Tüzün  et  al.,  1996],  and  a  higher  prevalence  of  370  per 
100,000 in a rural  area in northern Turkey [Yurdakul  et  al.,  1988].  The 
prevalence in Japan, Korea, China, Iran, and Saudi Arabia ranges between 
13.5  to  20  cases  per  100,000,  whereas  it  is  lower  in  Western  countries 
ranging between 0.64 per 100,000 in the United Kingdom and 0.12 to 0.33 
per 100,000 in the United States, 21 per 100,000 among citizens of Turkish 
origin in Germany and 0.42 to 0.55 per 100,000 among German natives 
[Sakane et al., 1999; Saylan et al., 1999]. A prevalence of 120 per 100,000 
was reported in an Arab community in Israel [Jaber et al., 2002]. 
Behçet’s disease is somewhat more common among females in Japan, 
Korea,  United  States  and Germany,  whereas  males  are  more  frequently 
affected in Middle Eastern countries  [Sakane  et  al.,  1999]. The male to 
female ratio is 3:2; however, males often have more severe disease [Önder 
and Gürer, 1999]. The onset of  BD occurs typically in the third or fourth 
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decade of life, and the frequency within families is 2% to 5% in Europe, 
while in Middle Eastern countries, it is 10% to 15% [Sakane et al., 1999]. 
I.1.3 Diagnosis
In the absence of a diagnostic laboratory test, BD is identified by 
clinical diagnosis, that is based on a proposed criteria by the International 
Study Group (ISG) for BD in 1990, as summarized in Table I.1 
[International Study Group for Behçet’s Disease, 1990]. The ISG criteria 
are widely accepted in Middle Eastern countries, whilst Japan, Korea, and 
other countries in the Far East use the revised Japanese criteria that consist 
of four major symptoms and a number of minor features [Saylan et al., 
1999]. The major symptoms include oral and genital aphthae, skin lesions, 
and ocular disease. Minor features include arthritis without deformity, 
neurological symptoms, gastrointestinal lesions, epididymitis, and vascular 
lesions [Behçet’s Disease Research Committee of Japan, 1974].
Inclusion of recurrent oral ulceration as a non-optional criterion may 
exclude approximately 3% of patients considered to have definite  BD, in 
whom the disease exists without a history of oral ulceration [International 
Study Group for Behçet’s Disease, 1990]. Besides, the ISG criteria omit the 
minor symptoms or signs that  may indicate a possible diagnosis  of  BD, 
such as arthralgias and arthritis;  subcutaneous thrombophlebitis,  deep vein 
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thrombosis, gastrointestinal ulcerations; and central nervous system disease 
involvement [Önder and Gürer, 1999].  
The  pathergy  test  is  useful  for  evaluating  skin  irritability  and  is 
considered a diagnostic criterion [International Study Group for Behçet’s 
Disease,  1990].  The  test  consists  of  pricking  a  sterile  needle  into  the 
patient's forearm. The results are judged to be positive by a physician, when 
the puncture causes an aseptic erythematous nodule or pustule that is more 
than 2 mm in diameter at 24 to 48 hours [Özarmagan et al., 1991; Akmaz et  
al., 2000]. Positive pathergy test is an important  parameter in the diagnosis 
of BD in Middle Eastern countries [Saylan et al., 1999].
The differential diagnosis of BD includes chronic oral aphthosis, 
herpes simplex virus infection especially with recurrent aseptic meningitis, 
Sweet’s syndrome, Stevens-Johnson syndrome, HLA-B27–related 
syndromes such as ankylosing spondylitis and Reiter's syndrome, and 
inflammatory bowel disease [McCarty, 1989; Sakane et al., 1999].
I.1.4 Clinical Manifestations
The  widespread  organ  involvement  in  BD is  well  recognized  as 
illustrated  in  Figure  I.1.  Remissions  and  exacerbations  characterize  the 
course of the disease [Verity et al., 2003]. 
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I.1.4.1 Oral Ulcerations
The  hallmark  of  BD is  recurrent  multiple  oral  ulcerations,  that 
sometimes precedes other manifestations by a number of years [Bang et al., 
1995]. The frequency of this finding is 96% to 100 % in Middle Eastern 
countries and Japan [Saylan et al., 1999; Sakane et al., 1999]. Painful oral 
ulcers   appear  in   the  gingiva,  tongue,  buccal   and   labial  mucosal 
membranes. The typical ulcer appears round, with a sharp, erythematous 
border,  and the surface is covered with a yellowish pseudomembrane as 
shown in Figure I.2-A [Kelley  et al., 1993]. Oral ulcers are typically the 
first to come and last to leave in the course of the disease and they may 
become less common after about 20 years of the disease onset [Bang et al., 
1995]. 
There are three types of aphthous lesions in  BD: minor, major, and 
herpetiform [Main and Chamberlain,  1992].  Minor ulcers  are  superficial 
with a diameter of 2 to 6 mm and appear as multiple lesions, developing 
within 1 to 2 days. They heal without scaring within 7 to 10 days and recur 
at  various  frequencies.  Major  ulcers  are  seen  less  frequently.  They  are 
deeper and painful, have a diameter of more than 10 mm with a grayish 
white ulcer base, and heal in 2 to 6 weeks leaving scars. The ulcers that are 
observed the least consist of the herpetiform variety. They are numerous, 
hundred  in  number and grouped as small ulcers with a diameter of  2  to  3 
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mm, and heal  in a short time [Main and Chamberlain,  1992; Önder and 
Gürer, 2001].
I.1.4.2 Genital Ulcers 
Genital ulcers consist one of the cardinal manifestations of  BD that 
occur in about 75% of patients. They are most commonly found on  the 
scrotum and penis in men and on the vulva in women as shown in Figure 
I.2-B.  Genital  ulcers  are  painful  and morphologically  similar to  the oral 
ulcers  but  they  are  usually  larger  and  deeper  with  an  irregular  margin, 
which recur in 3 weeks and usually leave scars. Recurrence is typically less 
frequent than oral ulcerations [Saylan et al., 1999; Kelley et al., 1993]. 
I.1.4.3 Cutaneous Manifestations
Cutaneous lesions  occur  in over  one-half  of  patients  with  BD. The 
most frequent cutaneous findings consist of papulopustular manifestations 
and erythema nodosum-like  signs  [McCarty,  1989].  Erythema nodosum-
like lesions are common in female patients and usually occur on the lower 
extremities, but can also be seen on the arms, neck and face. The areas of 
erythema are slightly elevated and characterized by painful livid, purple-
colored nodules surrounded by a peripheral halo as shown in Figure I.2-D. 
Their  numbers  can  be  restricted  to  three  to  four  or  they  may  be  more 
numerous.  These  lesions  are  usually  resolved  spontaneously,  leaving  a 
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deeply pigmented area, but they sometimes ulcerate [Sakane  et al., 1999; 
Önder and Gürer, 1999]. 
Papulopustular  eruptions  are  a  neutrophil-induced,  vessel-based 
reaction, referred to as "pseudofolliculitis" lesions that are common in male 
patients and are distributed on the back, face, and neck, especially along the 
hairline. The other types of papules are observed in the extremities [Saylan 
et al., 1999; Önder and Gürer, 2001]. 
I.1.4.4 Ocular Lesions
Inflammation of the eye is the main cause of morbidity in patients with 
BD, and affects 50% to 70% of men and 20% to 30% of women [Yazici, 
2002]. Although it typically occurs after the onset of oral aphthosis, the 
delay between the two may be as long as 14 years. Conversely, intraocular 
inflammation is the presenting feature in over 10% of patients, and in rare 
cases oral aphthosis may not occur at all [Verity et al., 2003].
Ocular involvement typically consists of a relapsing pan uveitis that 
affects both the anterior and posterior chambers and of episodes of retinal 
vasculitis [Nussenblatt, 1997]. The majority of ocular cases eventually 
suffer bilateral disease, but in 6% of cases, the disease remains uniocular. 
Patients with anterior ocular problems have better visual prognosis than 
posterior uveitis, but the later is more common. The cumulative destruction 
caused by the attacks and the vasculitic involvement of the optic nerve and 
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retinal vessels result in permanent visual loss [Önder and Gürer, 1999; 
Nussenblatt, 1997]. 
Hypopyon, a visible layer of pus in the anterior ocular chamber, is 
characteristic of BD, observed in 6–30% of the patients as shown in Figure 
I.2-C [Sakane et al., 1999].
I.1.4.5 Articular Manifestations 
Articular findings are observed in about 50% of the patients with BD 
and constitute one of the major manifestations of the disease. It can be seen 
as arthralgias or arthritis. The pattern is monoarticular or oligoarticular, 
although a symmetric or asymmetric polyarthropathy may also occur. 
Arthralgias are always more frequent than true arthritis, but arthritis itself 
develops in more than half of the patients. The knee is most commonly 
involved, followed by the ankle, elbow, and wrist; small joints are less 
commonly involved [McCarty, 1989; Yurdakul, 1983].  
Onset of arthritis tends to be insidious and duration variable, ranging 
from few weeks to several years. The intervals between arthritic attacks 
tend to be longer than those between attacks of extra-articular 
manifestations. Morning stiffness is present, while permanent changes and 
disability of the joints are rare [Önder and Gürer, 1999; Yurdakul, 1983].
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I.1.4.6 Vascular Manifestations
The vasculopathy of BD is unique, and although involvement of blood 
vessels of all types and sizes is a prominent feature of the disease, veins are 
affected more often than arteries. The vascular involvement which occurs in 
approximately 25% of the patients with BD includes both venous and 
arterial thrombosis, small vessel vasculitis, and arterial aneurysms [Koç et  
al., 1992; Kiraz et al., 2002]. It is usually seen in the first 5 years and can 
be the initial symptom, besides, it is more frequently and severe in males. 
Superficial thrombophlebitis is the most frequent form of venous 
involvement seen in a frequency of 7.3% as an initial finding whereas it 
occurs in 38% of the cases during the course of the disease, followed by 
deep venous thrombosis (DVT) especially in the lower extremities [Koç et  
al.; Saylan et al., 1999].  
Occlusion in large vessels especially that of superior and inferior vena 
cava and the hepatic vein is common. Arterial involvement is more rare 
compared to venous involvement (12% compared to 20-40% of all vascular 
involvement) but has a greater morbidity. Multiple spindle-shaped 
aneurysms are the most common lesions and predominantly affect the aorta, 
renal arteries, and popliteal arteries. Vascular lesions in the lung, cause 
recurrent episodes of dyspnea, cough, chest pain, and hemoptysis. 
[Hassikou et al., 2002; Kiraz et al., 2002].
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I.1.4.7 Neuro - Behçet’s Disease
Neurological involvement is noted in 5% to 10% of patients, 
particularly males in whom the disease began at an early age. It appears 
mainly in the parenchymal form (80%) or as dural sinus thrombi (20%). 
The parenchymal form has a more serious prognosis that is usually 
associated with brain stem involvement; whereas the dural sinus thrombi 
are associated with headache and intracranial pressure [Akman-Demir et  
al., 1999; Yazici, 2002]. 
I.1.4.8 Gastrointestinal Involvement
Gastrointestinal involvement in BD can present as ulcerative lesions, 
most frequently occurring in the ileocaecal regions, but ulcers have been 
described in other parts of the small and large bowel as well as the 
esophagus and stomach. Gastrointestinal involvement causes abdominal 
pain, diarrhea, melena, and sometimes perforation. These findings are more 
common in Japan (10% to 40%) and rare in Mediterranean countries (for 
example 1% in Turkey) [Chung et al., 2000].
I.1.4.9 Other Rare Findings
Renal Behçet’s disease is most often mild in nature. 
Glomerulonephritis, amyloidosis, renal vascular involvement, interstitial 
nephritis, and other problems, such as complications of drug therapy or 
genitourinary system abnormalities have been associated with BD. The 
16
frequency of renal problems among BD patients has been reported to vary 
between 0% to 55%. Male gender is a risk factor for all types of renal BD 
[Akpolat et al., 2002a]. Cardiac complications in BD have been reported 
relatively rarely. Pancarditis, acute myocardial infarction, conduction 
system disturbances, and valvular disease have been described. Intracardiac 
thrombus formation is very uncommon [Türsen et al., 2002]. Muscular 
involvement in BD has been disclosed in only few cases. It presents as a 
predominantly myositic lesion, localized mostly in the lower extremities, 
although in few cases, other localizations may occur such as right arm and 
generalized weakness [Worthmann et al., 1996]. Epididymitis, fever, 
hearing disturbances and headache may also occur in patients with this 
disorder [McCarty, 1989].
I.1.5 Pathology
Behçet’s disease is a systemic perivasculitis, in which early neutrophil 
infiltration,  endothelial  cell  swelling,  and  fibrinoid  necrosis  are  well 
described [Ergun et al., 1998]. Significant neutrophil infiltration is seen in 
all  early  lesions,  including  mucocutaneous  aphthae,  pathergy  reaction, 
nodular  cutaneous  lesions,  and  ocular  lesions  [Hegab  and  Al-Mutawa, 
2000]. Neutrophils  from  patients  with  BD  have  increased  superoxide 
production, enhanced chemotaxis, and excessive production of lysosomal 
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enzymes,  indicating  that  the  neutrophils  are  overactive,  which  leads  to 
tissue injury [Fordham et al., 1982; Takeuchi et al., 1981; Efthimiou et al., 
1989; Freitas et al., 1998]. In addition, serum levels of neutrophil priming 
cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and 
IL-8 have been reported to be elevated [Mege et al., 1993].
I.1.6 Etiopathogenesis
Behçet’s disease is a polyfactorial disease, associated with multiple 
hereditary and environmental risk factors, as illustrated in Figure I.3 [Verity 
et al., 2003]:
I.1.6.1 Behçet’s Disease-An Infective Etiology
Two areas of research now support a microbial role in the BD. First; 
skin and peripheral blood monocytes have been shown to exhibit a 
hypersensitivity response to certain Streptococcus sanguis antigens in 
patients but not in healthy controls [Verity et al., 2003]. These bacterial 
antigens share amino acid sequences in common with one class of cell 
membrane proteins called heat shock proteins (HSP), which are expressed 
on cell membranes in response to physiological shock and microbial 
challenge. Several groups have demonstrated that both Streptococcus 
sanguis and the human HSP  (especially the  60/65 kDa HSP)  activate  γδT 
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cells in patients but not controls. This observation has led to the suggestion 
that, following bacterial challenge, oral mucosal cells express HSP which 
are antigenic and lead to antimucosal T cell cross reactivity in susceptible 
individuals [Direskeneli, 2001; Freysdottir et al., 1999].  On the other hand, 
serum antibodies to herpes simplex virus (HSV)-1 and circulating immune 
complexes with HSV-1 are both reported to be raised in BD patients 
[Direskeneli, 2001]. Moreover, HSV DNA has been demonstrated in the 
genital and intestinal ulcers of patients with BD, but not in oral ulcers [Lee 
et al., 1996]. Second, an animal model for BD was described in 1998, in 
which 30% of HSV-1 inoculated mice were reported to exhibit BD-like 
symptoms, which included skin, tongue, gastrointestinal and genital ulcers, 
ocular inflammation and arthritis [Sohn et al., 1998].
I.1.6.2 Heritable Risk Factors for Behçet's Disease
Family Studies
Behçet’s disease is not a monogenic disorder, and no clear Mendelian 
pattern of inheritance has yet emerged. Nevertheless, a number of features 
point to a genetic etiology. The unusual geographical distribution of disease 
and its close association with the major histocompatability complex (MHC) 
allele HLA-B51 are perhaps the strongest indicators that certain gene(s) are 
either directly responsible for disease, or promote indirectly the 
20
characteristic underlying inflammatory changes [Verity et al., 1999a]. 
Furthermore, familial aggregation in BD is well recognized [Koné-Paut et  
al., 1999]. Recently, the sibling recurrence risk ratio (λs) among  patients 
in  Turkey  is  reported  to  be   11.4 – 52.5  that  support  a hereditary basis 
for BD  [Verity et al., 2003]. Further evidence for hereditary risk factors is 
the finding of genetic anticipation in BD, in which earlier disease onset is 
encountered in children of affected parents [Fresko et al., 1998].
HLA-B51
A heritable risk factor for BD was first identified in 1982, when an 
association with HLA-B5 in the human MHC was first reported [Ohno et  
al., 1982]. In the great majority of racial groups particularly those from the 
Middle to Far East, the greatest heritable risk factor for BD, and  indeed for 
ocular disease or progressive central nervous system disease severity, is 
HLA-B51 [Mizuki et al., 2000; Mizuki et al., 2001; Verity et al., 1999b]. 
HLA-B51 is relatively frequent, ranging from 50% to 80% in patients in 
many ethnic groups, as compared with 10% to 20% in healthy individuals, 
with relative risk ranging from 1.38 to 20.70 [Sano et al., 2001; Cohen et  
al., 2002]. Recent data indicate that while at least 21 different alleles may 
exist at the HLA-B*51 locus, both HLA-B*5101 and HLA-B*5108 are 
associated with BD [Paul et al., 2001; Mizuki et al., 2002]. Where HLA-
B*51 is common, BD is encountered, and where this allele is rare, so too is 
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disease. However, HLA-B*51 cannot be the sole causative factor for the 
simple reason that roughly a third group of patients, even in countries with 
high disease prevalence, do not possess this gene [Verity et al., 2003]. 
Furthermore, the odds ratio (OR) of BD in an individuals positive for HLA-
B*51 shows a variation from 1.5 to 16 in different series [Verity et al., 
1999a]. 
Tumor Necrosis Factor
An association between BD and alleles in the TNF promoter region is 
reported in Japanese and Middle Eastern patients [Mizuki et al., 1992; 
Verity et al., 1999b]. Two possible alleles may exist at the promoter site, 
TNFB*1 and TNFB*2 [Pociot et al., 1993; Wilson et al., 1997]. The latter 
is associated with higher TNF production by stimulated monocytes, and 
might therefore lead to a more severe and prolonged inflammatory response 
than the former and is not only more prevalent among patients with BD but 
is also weakly associated with a poor visual outcome. However, the 
TNFB*2 allele is also in linkage with HLA-B51, and these two alleles may 
therefore be co-inherited, each contributing both to disease risk and to 
severity of organ involvement [Verity et al., 1999b; Verity et al., 2003].  
MHC Class I Chain Related Gene 
The MHC class I chain related A (MICA) gene appeared to be a strong 
candidate as the gene responsible for susceptibility to BD based on its 
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chromosomal localization [Bahram et al., 1994], its restricted and heat 
shock-induced expression in epithelial cells [Groh et al., 1996], its 
predicted immunologic function as a ligand of γδ T cells [Groh et al., 
1998], and a strong associations between certain alleles of the MICA gene 
(MICA-A6 and MIC-A009) and BD [Mizuki et al., 1997; Wallace et al., 
1999]. Subsequent analysis revealed a tight linkage between these alleles 
and HLA-B51, which itself remained the strongest genetic risk factor for 
BD [Mizuki et al., 2000].
Factor V Leiden Mutation 
In 1994, the molecular basis of activated protein C resistance (APCR) 
was discovered in Leiden Holland, and has been shown to be a single point 
mutation  in  the  coagulation  factor  V  gene,  which  results  from a  G→A 
transition  (CGA→CAA)  at  nucleotide  position  1691,  leading  to  the 
substitution of arginine by glutamine at amino acid position 506 [Bertina et  
al.,  1994].  Factor  V  Leiden  was  found  in  ~20–40  %  of  patients  with 
idiopathic DVT and it is also suggested that this mutation increases the risk 
of DVT in BD [Gül  et al., 1996; Koşar  et al., 2002; Kiraz  et al., 2002]. 
Furthermore,  Factor  V  Leiden  mutation  is  found  to  be  associated  with 
ocular BD [Verity et al., 1999c].
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ICAM-1 Gene Polymorphisms
The intercellular adhesion molecules-1 (ICAM-1) gene is  known to 
contain at least two polymorphic sites, situated at codon 241 (GGG→AGG; 
Gly→Arg) and at codon 469 (AAG→GAG; Lys→Glu) [Vora et al., 1994]. 
The  gene  products  of  these  two  regions  are  thought  to  correspond  to 
structural domains in the ICAM-1 molecule which are involved in ICAM-1 
binding to the Mac-1 leukocyte ligand (codon 241) and leukocyte LFA-1 
(codon 469), and it has been hypothesized that the two mutations, G241R 
and K469E, result in more effective binding of ICAM-1 to Mac-1 and LFA-
1, thereby enhancing the inflammatory response [Vora et al., 1994; Joling 
et al., 1994]. Evidence that ICAM-1 is involved in the pathogenesis of BD 
comes  from  histological  studies  of  BD  lesions  in  which  ICAM-1  is 
expressed and from reports that levels of soluble ICAM-1 (sICAM-1) are 
not  only  increased  in  the  disease,  but  are  also  associated  with  disease 
activity [George et al., 1997; Verity et al., 2000]. While the pathogenic role 
of  these  polymorphisms  is  unknown,  studies  show  that  the  ICAM-1 
mutations  are  associated  with  BD susceptibility  in  different  populations 
[Verity et al., 2000; Kim et al., 2003].
IL-1 Gene Polymorphisms
Serum levels of pro-inflammatory and Th1-type cytokines, including 
IL-1, have been reported to be elevated in BD [Yosipovitch et al., 1995]. In 
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addition, peripheral blood monocytes from patients with BD produce 
significantly more IL-1 when stimulated with bacterial lipopolysaccharide 
(LPS) than monocytes from normal controls or from patients with other 
inflammatory diseases [Mege et al., 1993]. Given the involvement of IL-1 
in BD, IL-1 gene cluster polymorphisms was investigated and suggested to 
be associated with an increased risk for BD by contributing to the enhanced 
inflammatory reactivity observed in these patients [Karasneh et al., 2003]. 
Susceptibility to BD is increased in individuals carrying both the IL-1A –
889C and IL-1B +5887T haplotypes. Individuals who are both homozygous 
CC at IL-1A –889 and TT at IL-1B +5887 appear to have twice the risk of 
developing BD as individuals having other IL-1A –889/IL-1B +5887 
genotypes [Karasneh et al., 2003].
I.1.7 Laboratory Findings
Laboratory findings are mainly nonspecific indices of inflammation. A 
mild  anemia  and  leukocytosis  is  observed  in  15%  of  chronic  patients 
[Saylan  et al.,  1999]. Patients with active disease may generate an acute 
phase response leading to a raised erythrocyte sedimentation rate (ESR), 
increased serum levels of C-reactive protein (CRP), and elevated plasma 
complement component such as C3, C4, C9, and Factor B [McCarty, 1989]. 
25
Elevated  IgG,  IgA,  IgM,  and  α2-globulin  are  often  seen  in  disease 
exacerbations [Önder and Gürer, 1999].
I.1.8 Treatment
The  main  objectives  of  BD  treatment  are  to  relieve  symptoms 
associated with mucocutaneous lesions and arthritis, control inflammation, 
minimize functional disability, and prevent recurrences. An outline of  BD 
management is presented in Table I.2. The choice of treatment is empirical 
that depends on the clinical presentation, the site, and the severity of the 
manifestations.  Priority  is  given  to  the  treatment  of  gastrointestinal 
symptoms, central nervous system involvement,  and large-vessel  lesions, 
which require high-dose corticosteroids, immunosuppressants, or both and, 
in some cases, surgical intervention. Treatment of ocular lesions requires 
more careful consideration than the treatment of mucocutaneous symptoms 
[Kaklamani and Kaklamanis., 2001; Sakane et al., 1999]. 
I.1.9 Prognosis
Clinical course of  BD is variable, even in an early stage, making it 
difficult to determine the long-term prognosis. Men appear to have poorer 
prognosis.  The  disease  usually  runs  a  protracted  course  with  attacks 
generally  lasting  for several weeks  and  recurring more frequently early in 
26
27
the  disease  [Önder  and  Gürer,  2001].  Mucocutaneous  and  arthritis 
involvements usually occur early. Chronic morbidity is usual; the leading 
cause is ophthalmic involvement, which can result in blindness. The effects 
of the disease may be cumulative, especially for neurologic, vascular, and 
ocular  involvement.  Mortality  is  low,  but  can  occur  from  neurologic 
involvement, vascular disease, bowel perforation, cardiopulmonary disease, 
or as a complication of immunosuppressive therapy [McCarty, 1989].
I.2 FAMILIAL MEDITERRANEAN FEVER
Familial Mediterranean fever (FMF) is an autosomal recessive disease, 
occurs  predominantly  in  populations  inhabiting  or  originating  from 
Mediterranean basin, namely Jews, Arabs, Armenians and Turks [Eliakim 
et  al.,  1981].  FMF  is  characterized  by  recurrent  episodes  of  fever  and 
serosal inflammation manifested by sterile peritonitis, pleuritis and arthritis 
[Langevitz et al., 1999].
I.2.1 MEFV Gene and Pyrin
The  gene  responsible  for  FMF,  denoted  MEFV  (short  for 
MEditerranean FeVer) is located on the short arm of chromosome 16 and is 
made  up  of  10  exons  [The  International  FMF  Consortium,  1997;  The 
French FMF Consortium, 1997]. MEFV encodes a 781 amino acids (aa) 
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protein  called  "pyrin"  for  its  role  in  the  regulation  of  pyrexia  by  the 
International consortium [The International FMF Consortium, 1997],  and 
"marenostrin" in allusion to mare nostrum, the ancient Latin name for the 
Mediterranean  Sea  by  the  French  consortium  [The  French  FMF 
Consortium,  1997],  that  is  predominantly  expressed  in  neutrophils  and 
cytokine–activated monocytes [Tidow  et al.,  2000].  Pyrin consists of six 
functional domains as illustrated in Figure I.4:
(i) a PYRIN domain (aa: 1 – 95) [Martinon et al., 2001],
(ii) a bZIP basic domain (aa: 266 – 280) [Shuman et al., 1990],
(iii) a B-box zinc finger domain (aa:  375 – 407) [Reddy  et al., 
1992],       
(iv) two overlapping nuclear localization signals (aa: 420 – 437) 
[Robbins et al., 1991], 
(v) an α-helical or coiled – coil domain (aa: 408 – 594) [Lupas, 
1997], 
(vi) a B30.2 or ret finger protein (rfp) (aa: 598 – 774) [Henry et  
al., 1997].
Although the C-terminal half of pyrin shares homology with several 
transcription  factors,  transfected  pyrin  localizes  in  the  cytoplasm  and 
interacts with microtubules via its N-terminal half [Mansfield et al., 2001].
A  hypothesis  postulates  that  the  normal  function  of  pyrin  is  to 
downregulate       granulocyte-mediated        inflammation,       either       by 
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downregulating  inflammatory  mediators,  microtubules,  or  adhesion 
molecules, or by transcriptional upregulating anti-inflammatory mediators 
[Samuels et al., 1998]. One of the most important advances in the past years 
has been the demonstration that the PYRIN domain is shared by a number 
of  proteins  involved  in  apoptosis  and  inflammation  and  is  the  fourth 
member of the six-helix bundle death domain-fold superfamily that includes 
death  domains  (DDs),  death  effector  domains  (DEDs),  and  caspase 
recruitment domains (CARDs) [Fairbrother  et al., 2001]. Similar to other 
members of this superfamily, the PYRIN domain appears to allow for the 
interaction, or assembly, of macromolecular complexes by PYRIN–PYRIN 
interactions [Liu et al., 2003]. Consistent with this,  in  vitro  studies  have 
demonstrated  pyrin  to  interact  specifically  with  another  PYRIN domain 
protein  denoted  apoptosis-associated  speck-like  protein  with  a  CARD 
(ASC) [Masumoto et al., 2001; Richards et al., 2001]. In addition to ASC 
N-terminal PYRIN domain, it contains a C-terminal CARD that specifically 
binds  the  CARD of  procaspase-1  [also  referred  to  as  IL-1β  converting 
enzyme  (ICE)],  leading  to  its  aggregation  and  autoactivation.  Activated 
caspase-1  then  processes  pro-  IL-1β  to  IL-1β,  which  is  secreted  and 
interacts with the IL-1 receptor to mediate inflammation [Srinivasula et al., 
2002; Stehlik  et al., 2003]. Recently, in vivo significant of the interaction 
between pyrin and ASC was established by demonstrating increased IL-1β 
processing  and  defective  LPS  and  IL-4-induced  apoptosis  in  peritoneal 
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macrophages from pyrin knockout mice. In this study, a proposed model of 
pyrin  in  regulating  ASC-mediated  caspase-1  oligomerization  and  IL-1β 
processing was defined as illustrated in Figure I.5 [Chae et al., 2003]. Pyrin 
also  inhibits  ASC-mediated  apoptosis  and  nuclear  factor-κB  (NF-κB) 
activation in transfected cells by disrupting: the interaction between ASC 
and cryopyrin [Dowds et al., 2003], and the interaction between ASC and 
Ipaf, thus inhibits NF-κB activation and apoptosis mediated by IκB kinase 
(IKK) and Caspase-8, respectively [Masumoto et al., 2003].
The anti-inflammatory role of pyrin has been further evidenced by the 
identification of mutations in proline serine threonine phosphatase-
interacting protein 1 (PSTPIP1), a protein that have been found to interact 
with pyrin in vitro, through pyrin's B-box zinc finger domain. The 
mutations in PSTPIP1 underlying pyogenic arthritis, pyoderma gangrenous, 
and acne (PAPA) syndrome lead to hyperphosphorylation and a marked 
increase in the strength of the interaction with pyrin. Increased pyrin- 
PSTPIP1 binding may, in turn, modulates pyrin's normal immunoregulatory 
function by preventing its interaction with other proteins such as ASC, thus 
sequesters pyrin, resulting in elevated IL-1β synthesis [Shoham et al., 
2003].
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I.2.2 MEFV Mutations
To date, about 53 MEFV mutations have been identified. 47 are 
missense mutations, one is nonsense mutation, two are insertion mutations, 
and three are small deletions as presented in Table I.3.
Mutations have been found in exons 1,  2,  3,  5,  7,  9 and 10 of the 
MEFV gene  as  shown in  Figure  I.6  [Hull  et  al., 2003].  There  are  two 
apparent  mutational  "hot  spots":  one  in  exon  10  and  one  in  exon  2. 
Remarkably, two hot spots are also contained within exon 10, one at codon 
680 [Dodé et al., 2000] and one at codon 694 [Bernot et al., 1998]. Three 
mutations have been identified at codon 680, and four mutations at codon 
694. Interestingly Y688X [Notarnicola et al., 2000], the sole premature stop 
codon found to date in FMF, is located between these two codons. In exon 
2,  two  mutations  have  been  found  at  codon  148  [Bernot  et  al.,  1998; 
Touitou,  2001].  In  addition,  a  number  of  MEFV  single  nucleotide 
polymorphisms (SNP) corresponding to silent substitutions have also been 
identified as shown in Table I.4.
In general, most missense mutations in MEFV gene resulted in a 
conservative change of a hydrophobic amino acid. Although this kind of 
amino-acid change often has little or no phenotypic effect, its impact can be 
much more dramatic [Touitou, 2001]. Several mechanisms – such as 
modification of conformation  or  stability,  alteration  of  a  binding  site  or 
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other sites of interaction – could account for phenotypic effects of such 
mutations [The French FMF Consortium, 1997].
I.3 ASSOCIATION BETWEEN BD AND FMF
Behçet’s disease and Familial Mediterranean fever, have for centuries 
been highly prevalent in the Middle Eastern and Mediterranean populations, 
namely in Turks, Arabs, and Non-Ashkenazi Jews (NAJ), and have been 
recognized as distinct entities on the basis of a panel of clinical features in 
the absence of a specific laboratory test [International Study Group for 
Behçet’s Disease, 1990;  Samuels  et  al.,  1998].  Both diseases are 
inflammatory, periodic, multisystemic, and share some common symptoms, 
such as: sterile inflammation, recurrent febrile attacks, abdominal and 
arthritic signs due to serositis, cutaneous features and acute scrotum [Drenth 
et al., 2001; Sakane et al., 1999]. It is interesting to note that, in patients of 
Mediterranean origin; these periodic conditions are sometimes difficult to 
distinguish because their main symptoms are not specific and may be 
associated in a same family and in a same patient. For example, recurrent 
fever, a key symptom in FMF, is also observed in pediatric BD patients 
[Touitou et al., 2000]. Furthermore, colchicine, a drug known to inhibit 
neutrophil chemotaxis, is extremely effective in preventing attacks of FMF 
and ameliorating some of the clinical manifestations of BD [Ben-Chetrit et  
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al., 1998]. In addition, the most severe complication of FMF is progressive 
amyloidosis of the AA type; BD may be complicated with amyloidosis of 
this type; which occurs to a lesser extent in BD patients than in FMF 
[Akpolat et al., 2002a; Grateau, 2000]. Vasculitis is usually considered to 
be the central pathological feature in BD, and although a possible 
autoimmune cause of FMF has not been confirmed, several vasculitis-
associated clinical entities among FMF patients, such as Henoch-Schönlein 
purpura, polyarteritis nodosa (approximately 5% and 1% respectively), and 
protracted febrile myalgia have been reported more commonly than in the 
general population [Ozen, 1999; Tekin et al., 2000]. As with FMF, the 
pathophysiology of BD is still unknown [Direskeneli, 2001; Ozen, 2003]. 
In both diseases, increased chemotaxis of neutrophils [Fordham et al., 1982; 
Territo et al., 1976] and high serum levels of IL-1β, IL-8, IL-6, and TNF-α 
have been described [Direskeneli et al., 1999; Mege et al., 1993; Baykal et  
al., 2003]. 
Recently, the possible association between FMF and BD has been of 
interest. A number of patients with FMF and BD (FMF-BD) have been 
described [Birlik et al., 1998; Schwartz et al., 2000; Ben-Chetrit et al., 
2002], and it was postulated that BD coexistence with FMF is higher than 
expected [Schwartz et al., 2000]. Furthermore, MEFV mutations have been 
associated with an increased risk of BD [Touitou et al., 2000] and, 
conversely, the presence of BD might increase the likelihood of a single 
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MEFV mutation causing FMF [Livneh et al., 2001]. Besides, Schwartz et  
al. has suggested that BD should be included among vasculitidis 
complicating FMF [Schwartz et al., 2000]. Moreover, a BD patient 
complicated with amyloidosis was reported to have M680I/M680I 
mutation, suggesting that the relationship between FMF and BD may be 
more complex than implied by the description of BD as a vasculitis 
complicating FMF [Akpolat et al., 2002b].
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CHAPTER II
MATERIALS AND METHODS
II.1 STUDY GROUP
II.1.1 Patients 
A total of forty four BD patients from different areas of the West Bank 
and Jerusalem were investigated in the present study, representing a total of 
88 independent alleles. All the patients were from Arab Palestinian descent, 
recruited  from  Makassed  Islamic  Charitable  Hospital,  Augusta  Victoria 
Hospital, and private clinics.
II.1.2 Diagnostic Criteria
Behçet’s  disease  patients  were  diagnosed  by  rheumatologists  and 
ophthalmologists. On the basis of the criteria established by the ISG for BD 
in  1991  [International  Study  Group  for Behçet’s  Disease,  1990],  the 
selected patients were divided into three groups:
• Definite type [D]: patients who fulfilled the ISG criteria for BD; that 
are, oral aphthous ulcers plus at least two of the followings: genital 
ulcers, eye lesions, and skin lesions (n = 28).
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• Probable  type  [P]: patients  who  manifested  at  least  two  of  the 
International criteria - oral ulcers plus one of the followings: genital 
ulcers, eye lesions, and skin lesions (n = 12).
• Suspected type [S]: patients with recurrent oral ulcers only (n = 4).
Pathergy test was not performed due to difficulties in following up BD 
patients and interpretation of its results after 24–48 hours. Personal, clinical, 
drug  therapy,  family  history,  and  specimen  information  of  the  studied 
patients were obtained through patients' interview, recorded on a standard 
clinical form. The age of onset was determined as the time of presenting 
manifestation attributable to BD, even if it is only aphthosis. 
To  assess  the  effect  of  MEFV  mutations  on  BD  expression,  BD 
patients were divided into 2 groups, one with MEFV mutations and one 
without  MEFV  mutations.  Then,  both  groups  were  compared  for  their 
varying demographic features and clinical manifestations of BD, such as 
age of onset, and the number of organs involved. Since there is no accepted 
clinical  severity index for BD, Table II.1 represents the severity  scoring 
system  utilized  in  this  study,  which  was  proposed  by  experienced 
rheumatologists  at  Makassed  hospital.  The  total  score  represented  an 
estimation of the disease severity and spread.
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II.2 SAMPLES PROCESSING
3 – 4 ml of blood was drawn from all participants into an EDTA 
Vacutainer tubes.
II.2.1 Buffy Coat DNA Purification Protocol
Genomic DNA was extracted from the buffy coat of blood samples by 
using a commercially available kit "MasterPureTM Genomic DNA 
Purification Kit for Blood Use" (Epicentre Technologies Co., U.S.A.), 
according to the following procedure:
• Blood samples were centrifugated at 1,000 rpm for 15 min.. 
Carefully, 600 µl of buffy coat were transferred into two 1.5 ml 
microcentrifuge tubes, each containing 300 µl and mixed thoroughly 
by vortexing.
• To lyse red blood cells, 1200 μl of Lysis Buffer 1 were added to each 
tube, inverted 3 times to be mixed and the tube bottom was flicked to 
suspend any remaining materials. The tubes were incubated for 5 
min. at room temperature, then inverted 3 times and flicked as 
outlined above. After continuing incubation for an additional 5 min., 
again the tubes was inverted 3 times and flicked. 
• The tubes were centrifugated at ≥ 15,000 rpm for 25 sec. in a 
microcentrifuge (Hettich, Germany).
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• The supernatant was discarded leaving approximately 25 μl of liquid. 
To white blood cells pellet so obtained 600 μl of Lysis Buffer 2 were 
added and pipetted up and down 5-7 times.
• 250 μl of Precipitation Solution were added and vortexed vigorously 
for at least 30 sec. leading to protein denaturation, then centrifuged 
for 10 min. at ≥ 15,000 rpm.
• The supernatant was poured into clean microcentrifuge tubes, and 
DNA was precipitated by adding 700 μl of cold isopropanol. 
Thereafter, the tubes were inverted several (30-40) times until a 
stringy DNA precipitate was visible. The DNA was pelleted by 
centrifugation at ≥ 15,000 rpm for 5 min..  
• Carefully, the supernatant was decanted without dislodging the DNA 
pellet, which then was washed twice with cold 75% ethanol, air dried 
at room temperature for a few min., dissolved in 70 μl of TE-Buffer 
and incubated overnight at room temperature.
II.2.2 Genomic DNA Quantification
The prepared DNA samples were diluted in TE-buffer in a ratio equals 
1:100. The optical density (OD) of this DNA dilution was measured at 260 
nm and 280 nm against plain TE-buffer as a blank using a 
spectrophotometer "GENE QUANT II" (Pharmacia Biotech, England). The 
48
OD reading at 260 nm allowed calculation of the nucleic acid concentration 
in the sample. An OD of 1.0 corresponds to approximately 50μg/ml of 
dsDNA. The concentration of the prepared DNA samples ranged from 
0.219–1.258 μg/μl with a protein concentration ranged from 0.1–2.5 mg/ml. 
The ratio of the readings at 260 nm and 280 nm (OD260/OD280) provided an 
estimate of the purity of the DNA. Pure preparations of DNA have 
OD260/OD280 value of 1.8. The ratio OD260/OD280 of the DNA samples 
obtained ranged from 1.7–2.0.  The OD at 320 nm was used for background 
compensation, whereas, OD at 230 nm was used as a guide for protein 
determination using the peptide bond absorbance. Finally, DNA samples 
were stored at –20ºC till further use.
II.3 MUTATIONS ANALYSIS
II.3.1 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) is an in vitro technique which allows 
the amplification of a specific DNA fragment that lies between two known 
DNA sequences. The basic components of a typical PCR mixture are: 
template DNA, buffer, dNTPs, primers, and the thermostable enzyme DNA 
polymerase. Initial denaturation of template DNA at 94-98ºC is sufficient to 
completely denature complex genomic DNA so that the primers can anneal 
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after cooling. The primer annealing step is an important parameter in 
optimizing the specificity of a PCR, and the calculated annealing 
temperature is used as a starting point for experimental work; however, the 
annealing temperature should also be optimized empirically. Primer 
extension is performed at 72ºC, which is the optimum temperature for Taq 
DNA polymerase [Newton and Graham, 1997; Dennis Lo et al., 1998]. 
II.3.2 Amplification Refractory Mutation System
Amplification Refractory Mutation System (ARMS) assay is a simple, 
rapid, and highly reliable molecular diagnostic method, used for detecting 
the presence of both MEFV point mutations and factor V Leiden mutation 
involving single-base changes in our study. A typical ARMS assay 
comprises two complementary PCRs; each conducted using the same 
substrate DNA. One reaction includes an ARMS primer specific for the 
normal DNA sequence that cannot amplify mutant DNA at a given locus. 
The second reaction includes a mutant-specific primer that cannot amplify 
normal DNA. A common second primer is used in both reactions as 
illustrated in Figure II.1. The allele specificity of these primers is conferred 
by the 3' nucleotide of the primer which complements one allele but not the 
other.  This  specificity  is   maintained   by   the   absence   of   a   3'   to   5' 
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proofreading activity in Taq DNA polymerase. ARMS assay has also been 
described in the literature as  allele-specific PCR (ASP), PCR amplification 
of specific alleles (PASA) and allele-specific amplification (ASA) [Newton 
and Graham, 1997; Dennis Lo et al., 1998]. 
One important consideration in an ARMS assay is designing primers 
which  are specific to  a  particular  gene  of interest. In our case the MEFV 
gene. Synthesized oligonucleotide primers of both L110P mutation (T→C 
transition at nucleotide 329) and P706 polymorphism (G→A transition at 
nucleotide  2118)  were  designed  and  supplied  by  the  manufacturer 
(GibcoBRL  Custom  Primers-Life  Technologies),  then  used  after 
reconstitution. Primers for other MEFV and factor V Leiden mutations were 
used  as  optimized  in  the  Molecular  Genetics  Laboratory  at  Makassed 
Hospital.
Thirty four MEFV mutations, nine MEFV polymorphisms, and factor 
V Leiden mutation were analyzed in this study. The MEFV mutations 
L110P, E148Q, E167D, T267I, P369S, R408Q, F479L, M680IGC, M694V, 
M694I, and V726A, P706 polymorphism, and factor V Leiden mutation 
were screened by using ARMS assay. Whereas, the remaining MEFV 
mutations I640M, P646L, L649P, R653H, E656A, D661N, S675N, G678E, 
M680IGA, M680L, T681I, Y688C, Y688X, I692del2074-2076, 
I692del2074-2076, M694del, M694L, K695R, V704I, I720M, A744S, 
P758S, and R761H, and the polymorphisms R652, S683, A701, S703, 
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F721, V722, D723 and G764 were screened by direct DNA sequencing of 
exon 10 of the MEFV gene. 
Table II.2 summarizes the primers and PCR conditions used in ARMS 
assay. PCR conditions for both L110P mutation and P706 polymorphism 
were calibrated to be used in this study, whereas the PCR conditions for the 
remaining  mutations  were  used  as  optimized  in  Molecular  Genetics 
Laboratory in Makassed Hospital. 
All PCR amplification reactions were carried out in  a final volume  of 
25  μl   and   performed  in  either  OmniGene  (Hybaid,  England)  or 
MiniCyclerTM (MJ Research INC., U.S.A.) containing 200 or 400 ng/μl of 
purified genomic DNA, 0.625U of Taq polymerase (Takara, Japan) and its 
1X buffer (10mM Tris-HCL, 50 mM KCL, 1.5mM MgCl2), 0.2 mM dNTPs 
mix and 200 ng/μl of each primer. 
PCR amplification conditions included an initial denaturation step at 
94ºC  for  9  min.,  followed  by  27-30  cycles  (mutation  dependent)  with 
second  denaturation  step  at  94ºC  for  15  sec.,  annealing  (depended  on 
primers used) for 15 sec., and extension at 72ºC for 30 sec., then a final 
extension step at 72ºC for 10 min.. 
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II.4 AGAROSE GEL ELECTROPHORESIS
The amplified PCR products were resolved by electrophoresis on a 2% 
agarose gels and stained with ethidium bromide for analysis, as previously 
described (Sambrook et al., 1989):
• The agarose gel (Techcomp, Ltd.) was prepared in 1X Tris-Acetate 
EDTA (TAE) buffer (0.04 M Tris-acetate, 0.001 M EDTA). The 
solution was cooled to 50–60ºC, and then ethidium bromide was 
added to a final concentration of 0.5μg/ml and mixed thoroughly.
• 10 μl of PCR products were mixed with 3 μl of Glycerol Based-
loading buffer which usually prepared as six-fold concentrated 
solutions (30% Glycerol in distilled water, 0.25% Bromophenol 
Blue, 0.25% Xylene cyanol FF).
• The obtained 13 μl were loaded in each of the wells formed in gel. 
DNA molecular weight marker was included in each gel to allow the 
estimation of the molecular weight of DNA fragments resolved.
• The horizontal gel was run with an overlay of 3–5 mm of 1X TAE 
running buffer that contained ethidium bromide to a final 
concentration of 0.5μg/ml. 
• A constant voltage of 100 V was applied using a power pack (Owl 
Scientific Plastic, Inc.). The run was stopped when the bromophenol 
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blue and xylene cyanol FF have migrated the appropriate distance 
through the gel.
• Gels were visualized under 300 nm UV Transilluminator (Dinco & 
Rheunium Industries, Ltd.) and photographed by the Polaroid 
GelCam camera (Polaroid, U.S.A.). 
II.5 DIRECT DNA SEQUENCING
The strategy for molecular detection of MEFV mutations that based on 
direct exon 10 sequencing after PCR amplification, is a rapid diagnostic aid 
performed in Molecular Genetics Laboratory at Makassed Hospital, as well 
as other molecular genetics laboratories protocol.
II.5.1 Exon 10 Amplification Conditions
Exon 10 was amplified with PCR in 100 μl reaction containing 400 
ng/μl of genomic DNA, 200 ng/μl of forward 
5'CCCGCAAAGATTTGACAGCTGTATC3' and reverse 
5'GGACAGATAGTCAGAGGAGCTGTGTTCTT3' primers, 0.2 mM 
dNTPs mix, 1X buffer (10mM Tris-HCL, 50 mM KCL, 1.5mM MgCl2) and 
2.5U of Taq polymerase (Takara, Japan). Cycling parameters included an 
initial denaturation step at 95ºC for 10 min., followed by 35 cycles of 95ºC 
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for 30 sec., 55ºC for 30 sec., 72ºC for 45 sec., and a final extension step at 
72ºC for 10 min.. 
The quality of the sequencing template is an important factor in the 
sequencing reaction. Thus the amplified PCR products of exon 10 which 
equal 435 bp were separated on 2% agarose gel and purified using GFXTM 
PCR DNA and Gel Band Purification Kit (Amersham Pharmacia Biotech). 
II.5.2 Exon 10 Fragments Purification from Gel Bands Protocol 
• An empty 1.5 microcentrifuge tube was weighted to the nearest 10 mg.
• Using a clean razor blade or scalpel, the slice of agarose containing the 
DNA band to be purified was excised, cut as close to the DNA band as 
possible and transferred to the pre-weighted 1.5 ml tube.
• The tube containing the agarose slice was weight to the nearest 10 mg, 
and the weight of the empty tube was subtracted to determine the 
weight of the slice.
• 10 μl of Capture Buffer was added for each 10 mg of gel slice. The 
contents were vortexed vigorously.
•  The tube was incubated at 60ºC for 15 min., until the agarose is 
completely dissolved.
• During the incubation, one GFX Column was placed in a Collection 
tube for each purification to be performed. 
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• After the agarose is completely dissolved, the contents were 
centrifuged briefly to collect the sample at the bottom of the tube.
• Thereafter, the sample was transferred to the GFX Column and 
incubated at room temperature for 1 min..
• The GFX Column and Collection tube were centrifuged in a 
microcentrifuge at full speed for 30 sec. The flow-through was 
discarded by emptying the Collection Tube into 1.5 ml tube, while the 
GFX Column was placed back inside the Collection Tube.
• 500 μl of Wash Buffer were added to the Column, and then 
centrifuged at 15,000 rpm for 30 sec.
• The Collection Tube was discarded, and the GFX Column was 
transferred to a fresh 1.5 microcentrifuge tube.
• 35 μl of elution buffer (autoclaved double-distilled water) were 
applied directly to the top of the glass fiber matrix of the GFX 
Column, incubated at room temperature for 1 min., and then 
centrifuged at full speed for 1 min. to recover the purified DNA.
• A capillary was dipped in the tube, filled with enough sample of the 
purified DNA for  measurement  that  prevented from leaking out by 
using Cristaseal,  and quantified by "GENE QUANT II" (Pharmacia 
Biotech, England). 
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• The following parameters: OD at 260 nm, 280 nm, 230 nm, 320 nm, 
OD260/OD280,  DNA  concentration  (μg/μl),  and  protein  concentration 
(mg/μl) against plain autoclaved double-distilled water as a blank were 
measured.  
II.5.3 Automated Sequencing
Direct DNA sequencing for the purified exon 10 of the MEFV gene 
was performed by using ABI PRISM 377 automatic sequencer at Hebrew 
University.  Sequencing  was  performed  in  one  direction,  the  forward 
direction.  Then sequenced product  of each sample was compared to  the 
wild-type  MEFV  gene  obtained  from  NCBI  Gene  Bank  (web  site: 
www.ncbi.nlm.nih.gov), accession number AF111163.
II.6 STATISTICAL ANALYSIS
Allele frequencies were estimated by direct counting. The distribution 
of  alleles  in  patients  with  Behçet’s  disease was  compared  with  that  of 
normal controls, and significance was tested by the Chi-square (χ2) test (2 
sided), while t test was employed for comparison of two independent means 
[Bourke et al., 1985]. Significance was assigned to P values < 0.05.
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III.1 CLINICAL DATA
Forty  four  patients  who  are  clinically  diagnosed  as  having  BD 
comprised the study population. Twenty five (25) of them were males and 
nineteen (19) were females, with a male to female ratio equals 1.3:1.0. The 
mean  ± SD age of the patients at study inclusion was  28.2 ± 12.7 years 
(range, 6 to 59). The mean age of onset was 21.2 ± 11.2 years (range, 2 to 
50).  The age at  onset  of disease is widely variable;  most patients  began 
having symptoms when they were under 30 years of age (34/44; 77.3%), 
whereas, in 22.7% of patients the symptoms appeared in the fourth and fifth 
decades of life as given in Table III.1. 
Twenty  eight  (64%)  patients  met  the  ISG criteria  for  BD  and had 
definite [D] disease, while twelve (27%) had probable [P], and four patients 
(9%) were suspected [S] to have BD. Besides, 25% of the patients had a 
familial BD history. The main clinical characteristics of the forty four BD 
patients  are  given  in  Table  III.2  and  the  frequency  of  these  features  is 
summarized in Table III.3. Recurrent oral aphthous ulcers, with or without 
other symptoms, is the most frequent feature, seen in all cases (100%). Oral 
ulcers are the sole compliant  in  9% of patients.  The  second  symptom,  in 
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order of frequency, has been genital ulcers (37/44; 84.1%), then 
arthritis/arthralgia seen in (30/44; 68.2%). Skin disease is found in 61.4% of 
cases while vascular and neurologic symptoms are observed in 11.4% and 
2.3% of cases, respectively. Eye involvement is diagnosed only in 7 
patients (15.9%), whereas gastrointestinal involvement and epididymitis in 
2 patients (4.5%) and 3 patients (6.8%), respectively. The frequency of the 
symptoms did not varied according to the age at onset, duration, and phase 
of the disease. Table III.4 shows the patterns of BD presentation, in which 
about half of the patients (47.7%) presented with oral ulcers, genital ulcers 
and skin lesions, followed by the presentation of oral plus genital ulcers in 
22.7% of patients. In only 6.8% of patients all the four sites were affected. 
III.2 DISTRIBUTION OF MEFV SEQUENCE VARIATIONS
Of the twelve MEFV variations analyzed by ARMS assay, seven 
MEFV mutations (E148Q, P369S, R408Q, F479L, M694V, M694I, and 
V726A), and one P706 polymorphism were detected in our samples, while 
four mutations (L110P, E167D, T267I, M680IGC) could not be identified. 
The results of a representative ARMS assay for MEFV mutations are shown 
in Figures III.1 and III.2. As most of MEFV mutations are clustered in exon 
10, its sequencing allows the detection of all known and potential new 
mutations in this region in a single-step reaction.  In addition,  it confers the 
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results of ARMS assay. Therefore, patients were further tested for less 
common mutations by direct DNA sequencing of exon 10 of the MEFV 
gene. This revealed the detection of A744S and V722M mutations and one 
polymorphism F721 in our studied patients. Representative results of 
sequence electropherograms are shown in Figures III.1 – III.3. 
Hence, by means of ARMS assay and direct DNA sequencing of exon 
10, eleven different MEFV sequence variations were detected in our 
samples. Eight mutations (M694V, M694I, V726A, E148Q, F479L, P369S, 
R408Q, and A744S) have been described elsewhere in FMF patients [The 
French FMF Consortium, 1997; Bernot et al., 1998; Cazeneuve et al., 1999; 
Aksentijevich et al., 1999]. Four of the eight mutations (V726A, M694V, 
M694I, and E148Q) have been previously described in BD patients 
[Touitou et al., 2000; Ben-Chetrit et al., 2002], whereas the other four 
mutations (F479L, P369S, R408Q, and A744S) were detected in BD 
patients for the first time in this study. Further, one, V722M (G→A 
transition at nucleotide 2164), is a novel MEFV mutation that have not been 
reported before in either FMF or BD patients. The two remaining MEFV 
sequence variations are MEFV polymorphisms, one of which (F721) is 
detected for the first time in BD patients, whereas the other polymorphism 
(P706) was reported before in BD patients [Touitou et al., 2000].
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The genetic test pointed out 18 patients (10 males and 8 females) of 
the  44  (40.9%)  with  at  least  one  MEFV  mutation  or  polymorphism. 
Fourteen patients (14/18; 77.8%) were heterozygotes for one mutation or 
polymorphism, three patients (3/18; 16.7%) were compound heterozygotes 
and one (1/18; 5.6%) had 3 mutations: E148Q, P369S, and R408Q. The 
distribution of MEFV genotypes in our BD patients is given in Table III.5. 
However,  no  homozygous  mutations  were  detected  in  our  studied  BD 
patients and no mutations were identified in 26 patients (59.1%), but we 
cannot exclude that some of our patients had still unknown mutations or 
rare mutations in other exons.
Four patients had two mutated alleles, and fourteen had one mutated 
allele; altogether 18 patients carried 22 mutations, a frequency of one 
mutation per 4 chromosomes tested (22/88). Thus, 25% of the total alleles 
(22/88) tested positive, while 75% of the total alleles (66/88) tested 
negative. Table III.6 summarizes the frequency of MEFV mutations among 
Palestinian BD patients. The most frequent MEFV mutation in our patients, 
who represent one of the populations commonly affected with FMF, was 
E148Q substitution, identified in 8 alleles (22.2%). Five patients were 
heterozygotes for E148Q mutation, two of them are brothers. Two patients 
were compound heterozygotes, once associated with M694V mutation and 
once with P706 polymorphism. The eight's patient has a complex allele in 
which E148Q was associated with both P369S and R408Q mutations. 
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M694V mutation was found in four alleles (11.1%). This mutation was 
found in heterozygous state in two patients, while in one patient M694V 
mutation was present with E148Q mutation, and in another with A744S 
mutation. V726A mutation was detected in three alleles (8.3%). All V726A 
mutations were detected in heterozygous state. Each of the remaining 
mutations: M694I, P369S, R408Q, F479L, A744S, and V722M, besides the 
polymorphisms P706 and F721 was found in one allele (2.8%). 
Table III.7 represents the distribution of MEFV genotypes according 
to BD status, in which a decrease in genetic variation of identified MEFV 
mutations from definite to suspected disease status can be noted. Out of the 
18 BD patients, 11 (61.1%), 5 (27.8%), and 2 (11.1%) were clinically 
diagnosed as having definite, probable, and suspected BD, respectively, and 
genetically bearing one, two, or three MEFV mutations or polymorphisms. 
It is interesting to note that the following mutations: M694V, M694I, 
E148Q, F479L, P369S, R408Q, and V722M, and the polymorphism P706 
were found in the definite BD patients. Whereas, the three mutations 
V726A, E148Q and M694V and the polymorphism F721 were found in the 
probable BD patients. Furthermore, M694V, V726A, and A744S mutations 
were detected in the suspected BD patients. Within the 28 cases of definite 
BD, compound heterozygosity and complex alleles was detected in 3 cases, 
heterozygosity   was   detected  in  8  cases;  in  17  cases  no  mutation  was 
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detected at all. Within the 12 cases of probable BD, only heterozygosity 
was detected in 5 cases; and no mutations were detected in 7 cases. Two 
genotypes were identified in the four suspected BD patients, one is 
heterozygous and the other is compound heterozygous. However, our data 
on probable and suspected BD patients are based on small numbers and 
therefore they must be interpreted cautiously. 
III.3 GENOTYPE – PHENOTYPE CORRELATION
The clinical severity index was calculated for each patient as shown in 
Table III.8. To determine whether the clinical severity of the BD correlated 
with MEFV genotype, the patients were pooled according to the presence or 
absence of MEFV mutations into two groups. Group one consisted of 18 
BD patients with MEFV mutations, while the other group consisted of 26 
BD patients with none of the targeted MEFV mutations. No significant 
differences were found among the two groups with regard to the prevalence 
of oral ulcers, genital ulcers, skin involvement, articular, or gastrointestinal 
as shown in Table III.9. In addition, both groups were almost similar for 
age of onset of BD and no correlation between severity of the disease and 
MEFV mutations were found in this study. P value was not significant in all 
cases. We then analyzed whether the presence of the MEFV mutations 
predisposed   to  a  particular  manifestation  of  the  BD  by  comparing  the
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clinical features among subgroups of patients with one or two MEFV 
mutated alleles versus patients who did not carry MEFV mutation, and 
again no relation was observed. Here, it is noteworthy to mention that 
within the cases we examined, no concomitant FMF was noted, nor any 
symptoms pointing to it, such as short episodes of fever, polyserositis, or 
erysipelas-like skin lesion.  
III.4 DISTRIBUTION OF FACTOR V LEIDEN MUTATION
Factor V Leiden mutation was detected in five (11.4%) of the forty 
four studied patients with Behçet’s disease. These patients (2 males and 3 
females) were diagnosed to have definite Behçet’s disease; among them 
four had a history of oral and genital ulcerations, and skin manifestations, 
and one manifested with oral ulcers, genital ulcers, and eye lesions. All the 
patients who tested positive were heterozygous for factor V Leiden 
mutation as illustrated in Figure III.4. Factor V Leiden mutation was 
detected in one (20%) of five patients with a history of thrombosis and in 
four (10.3%) of thirty nine patients without a history of thrombosis (P value 
is not significant).
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DISCUSSION
The  present  study  focuses  on  the  genetic  background  of  BD,  that 
includes the screening for MEFV and factor V Leiden mutations among 
Palestinian patients. The diversity and the frequency of the mutated alleles 
in these patients reflect the importance of our study, by  providing further 
genetic  argument  that  the  MEFV gene  mutations  may participate  in  the 
expression of inflammatory diseases other than FMF.
Four patients carried two mutated MEFV alleles, and fourteen had one 
MEFV mutation. Altogether, 22 of the 88 chromosomes studied (1:4) bore 
an MEFV mutation. Most importantly, 9% of our study cohort carried two 
mutated alleles. The prevalence of MEFV mutations in our patients with 
BD (40.9%)  significantly  exceeds  the  prevalence  previously  determined 
among the general Israeli-Arab population (10.4%) [Shinawi et al., 2000], 
P <0.01. 
Delineation of MEFV sequence variations in our patients led to the 
identification  of  nine  different  MEFV  mutations  and  two  MEFV 
polymorphisms. The E148Q mutation, which is not part of any recognizable 
motif or domain in the pyrin, is found in all ethnic groups suffering from 
FMF, and has been suggested to be a mild mutation with low penetrance 
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[Aksentijevich  et al., 1999; Cazeneuve  et al., 1999; Yilmaz  et al., 2001], 
represents  the  most  prevalent  mutation  observed  in  22.2%  of  the  total 
alleles. Hence, the over–representation of E148Q mutation in BD might to 
be  restricted  to  ethnic  groups  commonly  affected  by  FMF  and  could 
actually be BD–associated since it exceeded that in FMF patients, in our 
data and in others [Ayesh et al., 2004; Touitou et al., 2000].
Five of the nine MEFV mutations and the two polymorphisms which 
were detected in 33.3% of alleles, are located in exon 10 and would be 
predicted to affect the secondary structure of B30.2 C-terminal domain of 
pyrin, which is crucial for the function of this protein and mutations at or 
near this region cause a disease [Kastner, 1998]. The M694V mutation 
which were found to be the most frequent and severe mutation in FMF 
patients [Touitou et al., 2001], was observed in 11.1% of alleles. While 
V726A mutation, a milder mutation than M694V [Touitou et al., 2001], 
was detected in 8.3% of alleles. Both M694V and V726A mutations are 
widely distributed in the Mediterranean basin [Kastner, 1998]. Although 
M694I mutation was found mainly in Arabs FMF patients [The French 
FMF Consortium, 1997], only one allele (2.8%) carried this mutation in this 
study. Out of the five most common mutations only M680I mutation was 
not detected in any of our patients. A744S mutation that is mainly confined 
to Arabs FMF patients [Touitou et al., 2001], accounted for 2.8% of alleles. 
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The novel missense mutation which was identified for the first time in 
the present study, V722M (GTG→ATG) is present only in one allele. A 
mutation that occurs in less than 1% of the alleles in the population is by 
definition rare and may be disease-causing, whereas a mutation that is 
found at higher frequency may be a neutral polymorphism. Reports of 
mutations resembling polymorphism should include the analysis of 100 
chromosomes or mention of frequency [Cotton and Scriver, 1998]. 
Although the functional significance of V722M mutation remains to be 
demonstrated, it occurs in exon 10, which is part of the rfp domain of the 
pyrin protein where most mutations, especially severe and frequent ones, 
are located. Besides, it was not found in about 592 patients, tested for 
MEFV mutations in Molecular Genetics Laboratory during the last five 
years [Unpublished Data]. The patient carrying this mutation was not 
carrying any other previously reported mutations in the MEFV gene.
In a previous study, the P706 polymorphism has been found to be the 
most frequent MEFV sequence variation detected in 10.5% of probable BD 
alleles, suggesting that it may be especially associated with incomplete or 
atypical BD [Touitou et al., 2000]. In the present study, this polymorphism 
appeared in one definite BD patient. Interestingly, another polymorphism 
corresponded to silent substitution: F721 (TTC→TTT) was detected for the 
first time in our BD patient. This polymorphism was detected before in 
FMF patients in our population [Unpublished Data] and in others 
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[http://fmf.igh.cnrs.fr]. Note that these two polymorphisms P706 and F721 
are within a small genetic region (aa: 692–726), being the target for 14 
FMF mutations and polymorphisms, is certainly critical for the MEFV 
function. A possible explanation how these intraexonic polymorphisms can 
affect the corresponding protein function may be a decrease in the MEFV 
mRNA stability. Another hypothesis is that the P706 and F721 
polymorphisms impair the gene regulation through a change in the 
tridimensional conformation of the DNA molecule [Touitou et al., 2000].  
Other MEFV mutations accounted for further 8.3% of alleles: P369S 
in 2.8%, R408Q in 2.8%, and F479L in 2.8%. The substitutions P369S, is 
six amino acids N-terminal to the B-box zinc finger domain [Aksentijevich 
et al.,1999]. Regarding the R408Q mutation, the substitution replaces a 
charged residue by a neutral amino acid; besides, this nonconservative 
mutation lies in a region that comprises the C-terminal residues of this 
domain [Cazeneuve et al., 1999]. Additionally, F479L resides within the α-
helical (coiled-coil) domain [Bernot et al., 1998]. P369S, R408Q, and 
F479L are mild mutations for FMF phenotype that could readily lead to 
conformational changes in the pyrin protein [Touitou, 2001]. Interestingly, 
the L110P mutation which represented previously 2.6% of BD alleles (in a 
French family) [Touiyou et al., 2000] was not identified in the present 
study. This mutation was not reported in Arab FMF patients before and we 
could not detect it in about thirty FMF samples [Unpublished Data]. On the 
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other hand, P369S, R408Q, F479L, A744S and V722M mutations, and 
F721 polymorphism are reported for the first time in BD patients in this 
study. By further studies, a specific relation between these MEFV 
mutations and BD might be observed.
Three preliminary studies have emphasized the significance of MEFV 
mutations among BD patients [Touitou et al., 2000; Ben-Chetrit et al., 
2002; Atagunduz et al., 2003]. These results indicate the involvement of 
MEFV mutations in BD susceptibility. However, Touitou et al. screened 57 
patients with BD (38 definite and 19 probable) from the following 
ancestries: Arabs, Turks, NAJ, Italians, and French [Touitou et al., 2000]. 
Ben-Chetrit et al. studied 53 patients with BD (Arabs and Jews) who 
fulfilled the ISG criteria, analysis of their genomic DNA for MEFV 
mutations revealed that 16 patients bore such mutations. Two of whom 
were homozygous for V726A and E148Q mutations and displayed FMF 
manifestations, including episodic peritonitis with fever and arthritis. None 
of the remaining 14 BD patients with a single MEFV mutation had any 
FMF manifestation [Ben-Chetrit et al., 2002]. Atagunduz et al. investigated 
three MEFV mutations (M694V, M680I, and V726A) in 57 Turkish 
patients suffering from BD. Fifteen BD patients were found to carry one 
single MEFV mutation (26%), compared to 9.1% of controls. Among 20 
BD patients with vascular involvement, 11 patients (55%) had MEFV 
mutations compared to 4 patients (11%) in the non-vascular group, leading 
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to the conclusion that MEFV mutations may act as a genetic susceptibility 
factor for vascular BD [Atagunduz et al., 2003]. 
The frequency of MEFV mutations among patients suffering from 
Behçet's disease in different studies is given in Table IV.1. Unfortunately, 
we could not get more information about Atagunduz et al. report to be 
included in the comparison with other studies. The present study represents 
the first genetic study of MEFV mutations among Palestinian BD patients. 
MEFV mutated alleles were identified in 25.0% by this research compared 
to 23.5% of alleles by Touitou et al., 17.0% of alleles by Ben-Chetrit et al., 
and 13.2% of alleles by Atagundaz et al.. The five most common MEFV 
mutations in FMF (M694V, M694I, V726A, M680I, and E148Q) accounted 
for 10.4% of the alleles in the different ancestries BD patients [Touitou et  
al., 2000], a result less than the approximately equal data: 18.2% of alleles 
among Palestinian BD patients in the present study and 17% of alleles 
among the Israeli Arabs and Jews BD patients [Ben-Chetrit et al., 2002]. 
The same observation was noted for M694V mutation, which was reported 
in 2.6% of alleles by Touitou et al., compared to 4.6% and 4.7% in our 
study and Ben-Chetrit et al. study, respectively. It is important to point out 
that M694V mutation was recently reported in 9.7% of the alleles 
[Atagundaz et al., 2003], a result that exceeds those in the previous 
mentioned reports and in the present study. One interesting finding in our 
study  is  the  frequency of  E148Q mutation observed in  9.1%  of alleles. It
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was higher than 5.2% and 5.7% of alleles reported in the other two studies 
[Touitou et al., 2000; Ben-Chetrit et al., 2002].
In addition, a preliminary partial MEFV mutation analysis suggested 
that about 60% of FMF patients, who also suffer from BD (FMF-BD), have 
only a single mutated MEFV gene [Livneh et al., 2001]. This report also 
suggested that FMF may be expressed in individuals harboring only one 
coding mutation in MEFV. These findings may reflect a more generalized 
rule, that FMF may be precipitated in carriers of a single mutated FMF gene 
by factors unrelated to other MEFV allele and suggest that the FMF 
phenotype in this cohort was associated with the simultaneous presence of 
BD. The FMF-BD relationship has been cautiously interpreted thus far; 
which deserves further clarification.
MEFV mutations among Palestinian BD patients show a diverse 
picture. They include common and rare mutations, severe and mild 
mutations, and not only heterozygous mutations but also compound 
heterozygous and complex alleles appeared. One striking feature of FMF is 
the description of complex alleles with three mutations [Touitou, 2001]. In 
this study, we identified the first BD patient having three different MEFV 
mutations: E148Q/P369S/R408Q, an observation that further documents the 
MEFV molecular diversity of the complex alleles found in BD. In theory, 
such alleles could arise either sequentially, by the occurrence of 
independent mutational events, or by intragenic recombinations between 
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simple alleles; in FMF, MEFV haplotype analyses rather favor the latter 
hypothesis [Bernot et al., 1998; Aksentijevich et al., 1999]. It is, important 
to point that 38.6% of BD patients are responding well to colchicine 
therapy, eight of them are heterozygotes or compound heterozygotes for 
MEFV mutations. Hence, it is considerable to direct physicians to the 
possible beneficial effect of colchicine therapy in BD patients having 
MEFV mutations. Two of four patients included in the present study that 
were considered to have suspected BD form, have V726A/- and 
M694V/A744S genotypes, were solely suffering from recurrent aphthous 
stomatitis (RAS). Keeping in mind that these patients are relatively young, 
aged (9, 10, 10.5, and 23 years old), and that this symptom sometimes 
precedes other manifestations by a number of years, it is reasonable to 
expect the appearance of other main related BD clinical features in the 
future. Unlike BD, RAS is the most common oral mucosal disease, 
affecting about 15–20% of the population, with the oral mucosa being the 
prime and only site of lesions [Freysdottir et al., 1999]. 
Perhaps the most interesting and provocative finding of this report is 
the demonstration that approximately half of BD patients (40.9%) has one, 
two, or three MEFV mutations and polymorphisms, which represents the 
sensitivity of testing these mutations in our BD samples. Our data, which 
include 44 BD patients along with the above finding, confirm that these 
mutations can be used to identify the molecular defect in Palestinian BD 
91
patients. Conversely, the sensitivity could be somewhat lower if there are 
patients with BD for whom we have not yet detected mutations on their 
chromosomes. Because only exon 10 was sequenced for all our BD patients 
but not the remaining exons, our study might have missed all other known 
and potentially new MEFV mutations.
All MEFV mutations detected in our study were either heterozygous 
or compound heterozygous. What advantage heterozygotes MEFV 
mutations might have – if any on BD patients? A number of FMF patients 
with only one MEFV mutation have been reported, despite the search for 
new mutations, makes the interpretation of this status difficult in 
populations where the frequency of the carrier of one copy of the gene is 
considered to be between 1/10 and 1/5. This finding suggests that other 
mutations remain to be discovered in other regions of the MEFV gene, but 
it cannot be excluded that heterozygotes may present mild or sometimes 
atypical signs of FMF [Dodé et al., 2000; Aksentijevich et al., 1999; 
Stoffman et al., 2000; Drenth et al., 2001]. Furthermore, it was postulated 
that carrying a single copy of a mutated gene produced a modified (but not 
abnormal) inflammatory response that may have been protective against 
some pathogen or class of pathogens endemic in the Mediterranean basin. It 
has been suggested that the role of pyrin in the control of inflammation may 
be consistent with heterozygotes exhibiting heightened response to certain 
organism(s) [The International FMF Consortium, 1997; Brenner-Ullman et  
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al., 1994]. Recent studies suggested that when pyrin is defective, the 
negative feedback may not be established resulting in more pronounced 
Th1 activity and IFN-γ [Aypar et al., 2003]. This level of augmented 
inflammation may be expected to predispose FMF patients and carriers of 
the MEFV mutations to have a pro-inflammatory state. This is evident by 
the report that healthy carriers of the MEFV mutations have modest but 
significantly elevated baseline plasma levels of the classic acute phase 
reactants C-reactive protein, suggesting that their general response to 
inflammatory stimuli may be upregulated [Tunca et al., 1999]. 
Upregulation of the inflammatory response in persons with pyrin mutations 
most likely favors inflammation in general and as such predisposes MEFV 
mutant carriers to BD and other vasculitides [Schwartz et al., 2000; Livneh 
et al., 2001; Touitou et al., 2000; Gershoni-Baruch et al., 2003]. Moreover, 
genetically ascertained FMF patients (homozygotes or compound 
heteroztgotes), significantly expressed lower levels of MEFV mRNA than 
did healthy controls. Message levels in healthy carriers were intermediate, 
which supports a true dose-response relationship between the number of 
mutations and the abundance of MEFV transcripts. The difference between 
healthy controls and healthy carriers was significant, demonstrating that the 
decrease in MEFV mRNA expression is related to a molecular defect 
independent of FMF symptoms [Notarnicola et al., 2002]. Livneh et al. 
hypothesized that a reduced level of functional pyrin, presumably 
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characterizing heterozygosity, on the one hand, and increased demand for 
pyrin, by activated granulocytes of BD, on the other, may ultimately lead to 
FMF attacks in FMF–BD patients [Livneh et al., 2001].  In addition, 
occasional reports of autosomal dominant FMF have often been discounted, 
on the basis that asymptomatic FMF carriers are common in certain 
populations, and give rise to pseudo-dominant inheritance [Booth et al., 
2000].
To interpret the correlation data between the genotype and phenotype, 
it is important to emphasize that all investigated patients were of Palestinian 
ancestry;  they  were  therefore  expected  to  share  common  genetic 
background,  thereby  allowing  correlation  studies  in  a  relatively 
homogenous  population.  However,  the  possibility  that  the  presence  of 
MEFV mutations  may aggravate  the  clinical  expression  of  BD was  not 
supported by our observation. That is, the group of BD patients with MEFV 
mutations was almost identical to the BD group without them regarding age 
of onset, organ involvement, and severity of the disease (P value was not 
significant). MEFV mutations were also apparently not associated with a 
particular  BD phenotype,  and  this  remains  to  be  confirmed  in  a  wider 
selection of patients. 
The demographic findings obtained from the Middle Eastern countries 
including ours are shown in Table VI.2. There is a slight preponderance for 
males   in  Turkey,  Iran,  Egypt,  Lebanon,  Jordan,  Greece,  and  Palestine
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whereas males predominate in Iraq, Kuwait, Tunisia, and Saudi Arabia 
[Saylan et al., 1999]. In these countries the disease is most frequently 
diagnosed in the third decade of life, in our study 29.5% of patients were 
diagnosed in the second decade of life, whereas, 25.0% and 22.7% of 
patients were diagnosed in the first and third decades of life, respectively. 
The most frequent manifestation of the disease, as seen in this table, 
consists of aphthous ulcerations.  The frequency of this finding is 96–100% 
in the Middle Eastern countries, while it is 96–98.2% in Japanese patients. 
Our results of the clinical expression of BD are in line with reports from 
Arab countries such as Saudi Arabia, Lebanon, Iraq, and Tunisia insofar as 
the percentage of patients with genital ulcers, skin manifestations, Arthritis, 
and gastrointestinal involvement in our study is similar to that found in 
most   of   the   series   studied   in those countries.  The  frequency  of  eye 
manifestations found in our study is low according to experience 
rheumatologists, it does not concur with that reported in other 
Mediterranean and Asian countries, and might be attributed, in part, to the 
type of patients included or selected in this study. In the Arab Palestinian 
community 28.8% of marriages among first cousins and 49.3% of 
marriages among members of the same clan (hamula) are consanguineous, 
according to the Palestinian Central Bureau of Statistics [Unpublished 
Data]. A positive family history was noted in quarter (25%) of our forty 
four patients with BD. Most cases of BD are sporadic in families and the 
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parents of the patients are unaffected, but a familial aggregation has been 
previously reported [Koné-Paut et al., 1999]. A high sibling recurrence risk 
ratio for BD indicates that strong genetic factors play a part in the 
mechanism for the familial incidence in this disease [Fresko et al., 1998].
Ethnic background is one of the major contributors to the risk of BD 
[Krause et al., 2001], but the possibility of an environmental influence 
cannot be ignored by the observation that BD is rare among Japanese 
immigrants in Hawaii and California, and that the prevalence of BD among 
citizens of Turkish origin in Germany is lower than that in Turkey [Sakane 
et al., 1999]. Moreover, two major factors modulating BD severity 
appeared to be the age at disease onset and patient's sex [Yazici et al., 
1984]. Since the extent of organ involvement and prognosis in BD varies 
widely from one patient to another, it is likely that not only one but several 
genetic regions contribute to disease risk and severity. No single causative 
gene for BD has emerged; the evidence indicates that the underlying 
immune events in BD are triggered by a microbial antigen and subsequently 
driven by genetic influences which control leukocytes behavior and the 
coagulation pathways. While HLA-B51 remains the strongest disease 
marker and is regarded as an important contributor to the risk of BD in 
different ethnic groups; up to 81% of Asian patients have this allele [Mizuki 
et al., 2000; Sakane et al., 1999], other polymorphic regions in MICA 
[Mizuki et al., 1997], TNF [Verity et al., 1999b], ICAM-1 [Kim et al., 
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2003] and IL-1 [Karasneh et al., 2003], may contribute to disease by 
modulating the inflammatory response, and thereby influencing the 
progression of systemic and ocular disease. Here, it may be suggested that 
MEFV mutations are among these risk factors in the ethnic groups in which 
are present, whereas other ethnic groups require other genetic predisposing 
factors. Indeed, most cases with BD and amyloidosis, besides the familial 
form of BD have been reported from the Middle East and Mediterranean 
countries rather than Japan where MEFV mutations are mostly prevalent 
[Akpolat et al., 2002]. These results provide additional evidence that the 
MEFV mutations are one of the risk factors in the development of BD. 
Since IL-1β is an important mediator of fever and inflammation that have 
been reported to be elevated in Behçet's disease [Yosipovitch et al., 1995], 
and pyrin is among the proteins involved in the IL-1 inflammatory pathway 
by inhibiting caspase-1 and IL-1β activation through interaction with ASC 
[Chae et al., 2003], it is tempting to speculate that pyrin play a key role in 
the pathogenesis of BD.
Vasculitis is the main pathological process in BD that can partially 
explain the thrombotic phenomena. Why such thrombosis is not so common 
in other vasculitides, and why it occurs in only about 25% of patients with 
BD, is still unclear. It is speculated that a combination of hyperactive 
coagulation pathways, hypoactive anticoagulation mechanisms, or 
hypoactive fibrinolysis generate a tendency for thrombogenesis in this 
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subgroup of patients with BD [Kiraz et al., 2002]. Thus, mutations of the 
genes encoding proteins of these pathways might cause a predisposition to 
venous thrombosis. The most common inherited coagulation defect 
associated with venous thrombosis is APCR. In the majority of the cases, 
APCR is the phenotypic manifestation of factor V Leiden mutation, which 
leads to a more slow degradation of the mutant factor by APC [Spek and 
Reitsma, 2000]. Most individuals are heterozygous for factor V Leiden, but 
homozygous individuals are also rather common. Heterozygotes have a 3 to 
8-fold increased risk for venous thrombosis, whereas homozygotes have a 
much higher risk, about 50- to 100-fold [Spek and Reitsma, 2000]. 
Different groups investigated factor V Leiden mutation in patients with BD, 
and their results are conflicting as given in Table IV.3. This genetic 
coagulation defect could be as high as 37.5% in BD patients with a history 
of DVT [Gül et al., 1996] or be as low as zero percent [Kiraz et al., 2002]. 
Likewise, while factor V Leiden mutation was significantly higher among 
BD patients, there was no significant difference between BD patients with 
or without venous occlusion [Toydemir et al., 2000]. Relied on several 
studies particularly Gül et al. report in 1996, factor V Leiden mutation was 
suggested to play a role in the hypercoagulable state of BD [Gül et al., 
1996].
Only five BD patients manifesting vascular involvement in the present 
study, and one of them was diagnosed to have factor V Leiden mutation. On 
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the other hand, thrombosis is absent in four definite BD patients carrying 
factor V Leiden mutation. However, heterozygous polymorphism for factor 
V is not uncommon in the general populations. In Lebanon it is found to be 
14.2%, in Syria 13.6%, and in Jordan 12.3% [Irani-Hakime et al., 2000], 
and accordingly, the presence of factor V Leiden mutation (11.4%) in our 
cases could be coincidental. Keeping in mind that, the small numbers of 
patients in our study group specially those suffering from thrombosis 
prevents any conclusions being reached. Moreover, since most of our BD 
patients with the mutant factor V do not universally demonstrate venous 
occlusions, there may be other contributing factor(s).  
To complete the picture in this study, it is important to determine the 
followings: First, since the pathergy test is one of the diagnostic criteria for 
BD and this was not performed in the investigation of our BD patients, a 
large number of patients who are considered to have probable or suspected 
BD may be positive to this test, thereby, increasing the number of patients 
having definite BD form included in this research. Second, HLA-B51 
typing may allow us to apply more accurate genotype-phenotype 
correlation. Third, statistically, the population comprising this study may 
not be enough to role out the correlation between MEFV mutations and the 
clinical manifestations or phenotypes in patients suffering from BD on one 
hand, and factor V Leiden mutation and venous thrombosis in these patients 
on the other hand. Therefore, studies of a larger cohort of patients would be 
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decisive in demonstrating the relation between MEFV mutations and factor 
V Leiden mutation and BD and if a particular mutation or combination of 
mutations are associated with BD. Forth, this study should include the 
screening of Palestinian healthy individuals in parallel to BD patients for 
the presence or absence of MEFV mutations and factor V Leiden mutation. 
Finally, it is noteworthy to mention that out of the 44 BD patients included 
in this study, 32 patients (72.7%) are from Hebron. Therefore, well-selected 
BD patients not restricted to a certain geographical area are needed.
In conclusion, we demonstrated and genetically confirmed that MEFV 
mutations do exit in Palestinian BD patients, and we have shown the 
diversity and the frequency of mutations in these patients which could 
probably reflect MEFV mutations profile in the Arab Palestinian BD 
patients. Our findings coincide with other reports, and may further establish 
this gene as an additional susceptibility genetic factor for BD. This provides 
important tools for adapting a molecular diagnostic test for the BD 
population and further investigations. As our study group represents a small 
sample of BD patients with 34 MEFV mutations and 9 polymorphisms had 
been screened, we came to the conclusion that the risk of BD is not as 
simple as explained by the presence of MEFV mutations. In order to solve 
this relationship, more population-based, epidemiological, well-collected 
data in world-wide collaborative studies are warranted.
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For future researches, I recommend to measure C5a inhibitor in BD 
patients based on the possible relation between C5a inhibitor and MEFV 
mutations [Matzner et al., 2000]. To apply a genotype-phenotype 
correlation data in BD patients, I recommend to screen for all known 
genetic loci proposed to date to be involved in the pathogenesis or 
susceptibility of BD, this may include the screening of: HLA-B51, MICA-
1, IL-1, ICAM-1, TNF, and MEFV genes altogether [Mizuki et al., 2000; 
Mizuki et al., 1997; Verity et al., 1999b; Kim et al., 2003; Karasneh et al., 
2003; Touitou et al., 2000]. The past 6 years have witnessed the 
identification of genes causing seven autoinflammatory diseases, in addition 
to FMF, most of them encodes proteins that are involved in the regulation 
of apoptosis, inflammation, and cytokine processing [Hull et al., 2003; 
McDermott, 2002]. Studying the similarities between these diseases and BD 
may enable us to identify new genes involved in BD pathogenesis.
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Table I.1 The International Study Group criteria for Behçet’s Disease*
Finding Definition
Recurrent oral ulceration
                                                       Minor aphthous, major aphthous, or 
herpetiform ulcers observed by the 
physician or patient, which have recurred 
at least three times over a 12-month 
period
Recurrent genital ulceration
                                                       Aphthous ulceration or scarring observed 
by the physician or patient
Eye lesions  
                                                       Anterior uveitis, posterior uveitis, or cells 
in the vitreous on slit-lamp examination; 
or retinal vasculitis detected by an 
ophthalmologist
Skin lesions 
                                                       Erythema nodosum observed by the 
physician or patient, pseudofolliculitis, or 
papulopustular lesions; or acneiform 
nodules observed by the physician in a 
postadolescent patient who is not 
receiving corticosteroids
Positive pathergy test 
                                                       Test interpreted as positive by the 
physician at 24 to 48 hours
*For the diagnosis to be made, a patient must have recurrent oral ulceration plus at least 
two of the other findings in the absence of other clinical explanations [International 
Study Group for Behçet’s Disease, 1990]. 
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Table I.2 Treatment for Behçet's Disease*
Treatment Dose Used as Used as 
                                                                  first-line therapy alternative therapy
Tropical corticosteroids
    Triamcinolone acetonide     3 times a day topically Oral ulcers
        ointment
    Betamethasone ointment     3 times a day topically                  Genital ulcers 
    Betamethasone drops          1 –2 drops 3 times daily                Anterior uveitis,retinal vasculitis
                                                         topically
    Dexamethasone                   1.0 –1.5 mg injected below Retinal vasculitis
                                                        Tenon ’s capsule for an
                                                         ocular attack  
Systemic corticosteroids
     Prednisolone                        5 –20 mg/day orally Erythema nodosum,anterior uveitis,retinal
  vasculitis, arthritis  
                                                 20 –100 mg/day orally            Gastrointestinal lesions,acute meningo-    Retinal vasculitis,venous thrombosis
                                                                                                  encephalitis,chronic progressive cen-
                                                                                                  tral nervous system lesions,arteritis
    Methylprednisolone            1000 mg/day for 3 days IV      Acute meningoencephalitis,chronic Gastrointestinal lesions,venous thrombosis
                                                                                                  progressive central nervous system
                                                                                                  lesions,arteritis
Tropicamide drops                  1 –2 drops once or twice          Anterior uveitis
                                                       daily topically
Tetracycline                            250 mg in water solution Oral ulcers
                                                       once a day topically
Colchicine                               0.5 –1.5 mg/day orally          Oral ulcers,†genital ulcers,†pseudo-              Arthritis 
              folliculitis,†erythema nodosum,
                                                                                               anterior uveitis,retinal vasculitis
Thalidomide                           100 –300 mg/day orally        Oral ulcers,†genital ulcers,†pseudofolliculitis †
Dapsone                                 100 mg/day orally                Oral ulcers,genital ulcers,pseudofolliculitis,erythe-
                                                                                                                                                            ma nodosum
Pentoxifylline                         300 mg/day orally                             Oral ulcers,genital ulcers,pseudofolliculitis,erythe-
                                                                                                                                                            ma nodosum
Azathioprine                           100 mg/day orally                                                                          Retinal vasculitis,†arthritis,†chronic progressive cen-
                                                                                                                                                            tral nervous system lesions,arteritis,venous throm-
                                                                                                                                                            bosis
Chlorambucil                          5 mg/day orally                                                                             Retinal vasculitis,† acute meningoencephalitis,,chron-
                                                                                                                                                          ic progressive central nervous system lesions,arteri-
                                                                                                                                                          tis,venous thrombosis
Cyclophosphamide                 50 –100 mg/day orally                                                                  Retinal vasculitis,acute meningoencephalitis,chronic
                                                                                                                                                          progressive central nervous system lesions,arteritis,
                                                                                                                                                          venous thrombosis
                                               700 –1000 mg/mo IV                                                                     Retinal vasculitis,acute meningoencephalitis,chronic
                                                                                                                                                          progressive central nervous system lesions,arteritis,
                                                                                                                                                          venous thrombosis
Methotrexate                          7.5 –15 mg/wk orally                                                                     Retinal vasculitis,arthritis,chronic progressive central
                                                                                                                                                          nervous system lesions
Cyclosporine‡                        5 mg/kg of body weight/              Retinal vasculitis†
                                                     day orally
Interferon alfa                        5 million U/day IM or SC                                                              Retinal vasculitis,arthritis
Indomethacin                         50 –75 mg/day orally                  Arthritis
Sulfasalazine                         1 –3 g/day orally                         Gastrointestinal lesions              Arthritis
Warfarin §                             2 –10 mg/day orally                    Venous thrombosis                    Arteritis
Heparin §                              5000 –20,000 U/day SC              Venous thrombosis                    Arteritis
Aspirin ¶                               50 –100 mg/day orally                Arteritis,venous thrombosis       Chronic progressive central nervous system lesions
Dipyridamole                       300 mg/day orally                        Arteritis,venous thrombosis       Chronic progressive central nervous system lesions
Surgery                                            —                                                                                         Gastrointestinal lesions,arteritis,venous thrombosis
* IV denotes intravenously, IM intramuscularly, and SC subcutaneously; †The efficacy of this 
drug for this use has been reported in controlled clinical trials; ‡Cyclosporine is 
contraindicated in patients with acute meningoencephalitis or chronic progressive central 
nervous system lesions; §This drug should be used with caution in patients with pulmonary 
vascular lesions; ¶Low-dose aspirin is used as an antiplatelet agent [Sakan et al., 1999].
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Table I.3 Description of the pyrin mutations
Usual Name         Location in the gene  Alteration        Sequence Variant    Protein Variant References
R42W Exon 1 substitution 124C>T Arg42Trp http://fmf.igh.cnrs.fr
S108R Exon 2 substitution 322A>C Ser108Arg http://fmf.igh.cnrs.fr
L110P Exon 2 substitution 329T>C Leu110Pro Domingo et al., 2000
334-335INSG Exon 2 insertion 335-336insG Glu112fsX241 http://fmf.igh.cnrs.fr
C.390-391INSGAGGGGAAC Exon 2 insertion       390_391insGAGGGGAAC    Asn130-Gly131insGluGlyAsn http://fmf.igh.cnrs.fr
E148Q Exon 2 substitution 442G>C Glu148Gln Bernot et al., 1998
E148V Exon 2 substitution 443A>T Glu148Val Tunca et al., 2000
E163A Exon 2 substitution 488A>C Glu163Ala http://fmf.igh.cnrs.fr
E167D Exon 2 substitution 501G>C Glu167Asp Bernot et al., 1998
E230K Exon 2 substitution 688G>A Glu230Lys Timmann et al., 2001
E251K Exon 2 substitution 751G>A Glu251Lys http://fmf.igh.cnrs.fr
T267I Exon 2 substitution 800C>T Thr267Ile Bernot et al., 1998
P283R Exon 2 substitution 848C>G Pro283Arg http://fmf.igh.cnrs.fr
G304R Exon 3 substitution 910G>A Gly304Arg http://fmf.igh.cnrs.fr
E319K Exon 3 substitution 955G>A Glu319Lys http://fmf.igh.cnrs.fr
R329H Exon 3 substitution 986G>A Arg329His http://fmf.igh.cnrs.fr
R354W Exon 3 substitution 1060C>T Arg354Trp http://fmf.igh.cnrs.fr
P369S Exon 3 substitution 1105C>T Pro369Ser             Aksentijevich et al., 1999
R408Q Exon 3 substitution 1223G>A Arg408Gln Cazeneuve et al., 1999
E474K Exon 5 substitution 1420G>A Glu474Lys http://fmf.igh.cnrs.fr
H478Y Exon 5 substitution 1432C>T His478Tyr http://fmf.igh.cnrs.fr
F479L Exon 5 substitution 1437C>G Phe479Leu Bernot et al., 1998
V487M Exon 5 substitution 1459G>A Val487Met http://fmf.igh.cnrs.fr
R501G Exon 5 substitution 1501C>G Arg501Gly http://fmf.igh.cnrs.fr
L559F Exon 7 substitution 1675C>T Leu559Phe http://fmf.igh.cnrs.fr
I591T Exon 9 substitution 1772T>C Ile591Thr Touitou, 2001
I640M Exon 10 substitution 1920C>G Ile640Met http://fmf.igh.cnrs.fr
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Table I.3 (Continued) Description of the pyrin mutations
Usual Name         Location in the gene  Alteration        Sequence Variant    Protein Variant References
P646L Exon 10 substitution 1937C>T Pro646Leu http://fmf.igh.cnrs.fr
L649P Exon 10 substitution 1946T>C Leu649Pro http://fmf.igh.cnrs.fr
R653H Exon 10 substitution 1958G>A Arg653His Timmann et al., 2001
E656A Exon 10 substitution 1967A>C Glu656Ala Touitou, 2001
D661N Exon 10 substitution 1981G>A Asp661Asn http://fmf.igh.cnrs.fr
S675N Exon 10 substitution 2024G>A Ser675Asn Dodé et al., 2000
G678E Exon 10 substitution 2033G>T Gly678Glu http://fmf.igh.cnrs.fr
M680L Exon 10 substitution 2038A>C Met680Leu Dodé et al., 2000
M680IGC Exon 10 substitution 2040G>C Met680Ile  French  FMF  consortium,  1997; 
         International FMF consortium, 1997
M680IGA Exon 10 substitution 2040G>A Met680Ile Aksentijevich et al., 1999
T681I Exon 10 substitution 2042C>T Thr681Ile Booth et al., 1998
Y688C Exon 10 substitution 2063A>G Tyr688Cys http://fmf.igh.cnrs.fr
Y688X Exon 10 substitution 2064C>G Tyr688X Notarnicola et al., 2000
I692DEL2074-2076 Exon 10 deletion              2074-2076del Ile692del http://fmf.igh.cnrs.fr
I692DEL2076-2078 Exon 10 deletion              2076-2078del Ile692del Bernot et al., 1998
M694DEL Exon 10 deletion               2078-2080del Met694del Booth et al., 1998
M694VExon 10 substitution 2080A>G       Met694Va  French FMF consortium, 1997;  
         International FMF consortium, 1997
M694L Exon 10 substitution 2080A>T Met694Leu http://fmf.igh.cnrs.fr
M694I Exon 10 substitution 2082G>A Met694Ile     French FMF consortium, 1997
K695R Exon 10 substitution 2084A>G Lys695Arg Bernot et al., 1998
V704I Exon 10 substitution 2110G>A Val704Ile http://fmf.igh.cnrs.fr
I720M Exon 10 substitution 2160C>G Ile720Met           Medlej-Hashim et al., 2002
V726A Exon 10 substitution 2177T>C Val726Ala  French FMF consortium, 1997;  
         International FMF consortium, 1997
A744S Exon 10 substitution 2230G>T Ala744Ser Bernot et al., 1998
P758S Exon 10 substitution 2272C>T Pro758Ser http://fmf.igh.cnrs.fr
R761H Exon 10 substitution 2282G>A Arg761His Bernot et al., 1998
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Table I.4 Description of the pyrin polymorphisms
Usual Name         Location in the gene  Alteration        Sequence Variant    Protein Variant References
Y65 Exon 1 substitution 195C>T Tyr65Tyr Bernot et al., 1998
D102 Exon 2 substitution 306C>T Asp102Asp          International FMF consortium, 1997
D103 Exon 2 substitution 309T>C Asp103Asp Bernot et al., 1998
P124 Exon 2 substitution 372C>T Pro124Pro http://fmf.igh.cnrs.fr
G138 Exon 2 substitution 414G>A Gly138Gly          International FMF consortium, 1997
L142 Exon 2 substitution 426G>T Leu142Leu       Medlej-Hashim et al., 2002
A165 Exon 2 substitution 495C>A Ala165Ala          International FMF consortium, 1997
R202Q Exon 2 substitution 605G>A Arg202Gln Bernot et al., 1998
S301 Exon 3 substitution 901C>T Ser301Ser          International FMF consortium, 1997
R314 Exon 3 substitution 942C>T Arg314Arg Bernot et al., 1998
P393 Exon 3 substitution 1179C>T Pro393Pro Bernot et al., 1998
   --- Intron 4 substitution         1356+43A>G       ---          International FMF consortium, 1997
E474 Exon 5 substitution 1422G>A Glu474Glu          International FMF consortium, 1997
Q476 Exon 5 substitution 1428G>A Gln476Gln          International FMF consortium, 1997
R501 Exon 5 substitution 1503C>T Arg501Arg Cazeneuve et al., 1999
I506 Exon 5 substitution 1518C>T Ile506Ile Cazeneuve et al., 1999
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Table I.4 (Continued) Description of the pyrin polymorphisms
Usual Name         Location in the gene  Alteration        Sequence Variant    Protein Variant References
D510 Exon 5 substitution 1530T>C Asp510Asp          International FMF consortium, 1997
   --- Intron 5 substitution         1588–69G>A             ---  Cazeneuve et al., 1999
   --- Intron 6 substitution         1610+95C>T              ---          International FMF consortium, 1997
   --- Intron 8 substitution         1756+8C>T       --- Cazeneuve et al., 1999
IVS8+8 C-T Intron 8 substitution 1759C>T       --- http://fmf.igh.cnrs.fr
   --- Intron 8 substitution         1764–30T>A       --- Cazeneuve et al., 199  
P588 Exon 9 substitution 1764G>A Pro588Pro          International FMF consortium, 1997
R652 Exon 10 substitution 1956G>A Arg652Arg http://fmf.igh.cnrs.fr
S683 Exon 10 substitution 2049G>A Ser683Ser Bernot et al., 1998
A701 Exon 10 substitution 2103G>A Ala701Ala http://fmf.igh.cnrs.fr
S703 Exon 10 substitution 2109C>T Ser703Ser http://fmf.igh.cnrs.fr
P706 Exon 10 substitution 2118G>A Pro706Pro Bernot et al., 1998
F721 Exon 10 substitution 2163C>T Phe721Phe http://fmf.igh.cnrs.fr
V722 Exon 10 substitution 2166G>A Val722Val http://fmf.igh.cnrs.fr 
D723 Exon 10 substitution 2169C>T Asp723Asp http://fmf.igh.cnrs.fr
G764 Exon 10 substitution 2292G>T Gly764Gly           Medlej-Hashim et al., 2002
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Table II.1 Behçet's Disease severity scoring system  
Clinical Feature Points
Oral ulcers 1
Genital ulcers 1
Skin lesions 1
    Erythema Nodosum 2
Eye 
    Anterior uveitis 1
    Posterior uveitis 2
    Blindness 3
Articular involvement
    Arthralgia 1
    Arthritis 2
Vascular involvement
    Superficial Thrombophlebitis 1
    Deep Vein Thrombosis 2
    Thrombosis of vena cava superior 3
Epididymitis 2
Gastrointestinal involvement 3
Neurological involvement 4
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Table II.2 Primers and PCR conditions used in ARMS assay
 
Primers                        DNA            Number                      Additives                        PCR
Mutation/                                                             concentration     Tm*     of cycles          DMSO†         Formamide          product 
Polymorphism Sequence (5'-3')  Type Reference           ( ng/μl)           (ºC)             (%)                   (%)                     bp‡ 
L110P                 CATGCGCACCACGCTCAGCTT Common Present Study               400            62          30               4                    2                     338
TCCTGGGCTTGTTCTCCCCCA Normal          
TCCTGGGCTTGTTCTCCCCCG Mutant
E148Q                 AGCCCCTGCAGCCTCCCCGCGGA Common Unpublished                 400            62          28                      _                    5                     228
CAGCCTGCGGTGCAGCCAGCCCG Normal Data
CAGCCTGCGGTGCAGCCAGCCCC Mutant
E167D                 TATTCCACACAAGAAAACGGCACAGATGATTCCGCAGCG Common Aksentijevich et al.,    200             60         30               _                        5                     259    
GGGCTCCGGGTCCGAGGCTTGCCCTGCGCGTCCAGGCCC Normal         1999
GGGCTCCGGGTCCGAGGCTTGCCCTGCGCGTCCAGGCCG Mutant
T267I                 CTGCGCAGAAACGCCAGCTCCGC Common Unpublished                 200            60          28              2.5                    5                      222
TTCTGTTGCCGAGTCCAGATTCGCAGCTG Normal Data
TTCTGTTGCCGAGTCCAGATTCGCAGCTA Mutant
P369S                 CCTGTAGCTCCCCTCTTTGCTGGACTGGTTTATATTGTG Common Unpublished                 200            67          28              _                    5                      353
CATGAAAGGAAGAGCCCGGGAAGCCTAAGCC Normal Data
CATGAAAGGAAGAGCCCGGGAAGCCTAAGCT Mutant
R408Q                 CCTGTAGCTCCCCTCTTTGCTGGACTGGTTTATATTGTG Common Unpublished                 200            67          28              _                         5                      234
AGTCTGAGTCAGGAGCACCAAGGCCACCG Normal Data
AGTCTGAGTCAGGAGCACCAAGGCCACCA Mutant
F479L                 TTCCAGCACGGCTGATGGCAGAGCTG Common Unpublished                200            60          28              _                    _                      273
TGTACTACTTCCTGGAGCAGCAAGAGCATTTC Normal Data
TGTACTACTTCCTGGAGCAGCAAGAGCATTTG Mutant
V726A                 TGGAGGTTGGAGACAAGACAGCATGGATCC Common Eisenberg et al.,          400            63          28              _                    _                      246
TGGGATCTGGCTGTCACATTGTAAAAGGAGATGCTTCCTA Normal         1998
TGGGATCTGGCTGTCACATTGTAAAAGGAGATGCTTCCTG Mutant
M680IGC                 TTAGACTTGGAAACAAGTGGGAGAGGCTGC Common Eisenberg et al.,          400            63          28              _                    5                      219
ATTATCACCACCCAGTAGCCATTCTCTGGCGACAGAGCC Normal         1998
ATTATCACCACCCAGTAGCCATTCTCTGGCGACAGAGCG Mutant
M694V                 TGACAGCTGTATCATTGTTCTGGGCTCTCCG Common Eisenberg et al.,           400             63         28              _                    _                      211
TCGGGGGAACGCTGGACGCCTGGTACTCATTTTCCTTCCT Normal         1998
TCGGGGGAACGCTGGACGCCTGGTACTCATTTTCCTTCCC Mutant
M694I                  CTGTATCATTGTTCTGGGCTCTCCG Common Unpublished                400             63         28              _                  2.5                     194
GGACGCCTGGTACTCATTTTCCTTC Normal Data
GGACGCCTGGTACTCATTTTCCTTT Mutant
P706                AAGTGGGAGAGGCTGCCTGATG Common Present Study              200             61         27                     _                   5                       268
GCTCCTTTATTAGCAGGCGGGTC Normal
GCTCCTTTATTAGCAGGCGGGTT Mutant
Factor V Leiden          CGCAGGAACAACACCATGAT Common Endler et al,                200             57           27              _                        _                    N:233 
AACAAGGACAAAATACCTGTATTCATC Normal         2001                                                                                                      M:246
GTCTGTCTGTCTCTTCAAGGACAAAATACCTGTATTCTTT Mutant
*Tm: Melting Temperature, †DMSO: Dimethyl Sulphoxide, ‡bp: base pair.
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Table III.1 Age distribution at onset of the disease
Number of patients Percentage (%)
First decade 11 25.0
Second decade 13 29.5
Third decade 10 22.7
Fourth decade 8 18.2
Fifth decade 2 4.6
Total 44 100
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Table III.2 Clinical features in Palestinian BD patients
Patient Sex* Age        Address   Age of    Disease    Oral    Genital    Eye      Skin  Other Features                               Family Mutation/
 Code (yr**)              onset(yr)   status§    ulcers    ulcers    lesions  lesions                                            History Polymorphism
BD1 F 23 Ramallah         19 D  Yes Yes         No         Yes             Arthralgia                  ---- Factor V Leiden
BD2 M 47 Hebron            10 D  Yes Yes         No         Yes             Arthritis, diarrhea, Epididymitis, SIJ†                 ----  ----
BD3 M 12 Hebron        8 D  Yes Yes         No         Yes             Arthritis, perianal scaring             BD brother E148Q/-
BD4 M 35 Hebron       10 D  Yes Yes         No         Yes             Arthritis, DVT‡, Thrombophlebitis, SIJ         Sisters with RAS║ E148Q/P706
BD5 M 31 Hebron            29 D  Yes Yes         No         Yes             Arthralgia, SIJ ----   ----
BD6 M 39 Hebron       10 D  Yes Yes         No         Yes             Arthritis, Epilepsy, SIJ ---- E148Q/-
BD7 M 25 Hebron       17 D  Yes Yes         No         Yes             Arthritis              BD brother + father with RAS E148Q/-
BD8 M 23 Hebron       10 D  Yes Yes        Yes        Yes             Arthralgia, SIJ              Brother with RAS F479L/-
BD9 M 6 Hebron       6 D  Yes Yes         No         Yes                       ----              BD father + brother ----
BD10 M 59 Hebron       45 D  Yes Yes         No         Yes             Arthralgia, Epilepsy              BD sun  ----
BD11 M 24 Hebron       16 D  Yes Yes         No         Yes             Arthritis, SIJ              Sister with RAS ----
BD12 M 47 Hebron       21 D  Yes Yes         No         Yes             Arthritis, SIJ              Sun with RAS Factor V Leiden
BD13 F 18 Hebron       14 D  Yes Yes         No         Yes             Arthralgia, SIJ              Sister with RAS       M694I/-, Factor V Leiden
BD14 F 39 Hebron       32 D  Yes Yes         No         Yes             Arthralgia, CNS┴ involvement ---- ----
BD15 M 13 Beit Jala       11 D  Yes Yes         No         Yes             Arthritis ---- ----
BD16 F 6 Nablus       2 D  Yes No          Yes        Yes        Hepatosplenomegaly, recurrent chest infections      ----     V722M/-, Factor V Leiden
BD17 M 42 Hebron       36 D  Yes Yes         No         Yes             SIJ              Children with RAS           E148Q/ P369S/ R408Q
BD18 F 30 Ramallah       24 D                Yes Yes         No         Yes            Arthritis ---- E148Q/-
BD19 M 25 Ramallah       18 D  Yes Yes         Yes        No            Stroke ---- ----
BD20 M 35 Ramallah       29 D  Yes Yes         Yes        Yes           Arthritis ---- ----
BD21 M 33 Al-Jeeb       28 D  Yes Yes         No         Yes            Arthritis, diarrhea, Epididymitis ---- ----
BD22 F 30 Hebron        27 D  Yes Yes         No         Yes            Arthritis, Gastrointestinal lesions              BD relatives M694V/E148Q   
BD23 M 39 Ramallah      28 D  Yes Yes         Yes       Yes            Arthritis, DVT ---- ----
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Table III.2 (Continued) Clinical features in Palestinian BD patients
Patient Sex* Age        Address   Age of    Disease    Oral    Genital    Eye      Skin  Other Features                               Family Mutation/
 Code (yr**)              onset(yr)   status§    ulcers    ulcers    lesions  lesions                                            History Polymorphism
BD24 F 32 Hebron      18 D  Yes Yes         Yes        No            Arthralgia              BD father ----
BD25 F 21 Hebron      18 D  Yes Yes         No         Yes            Arthritis ---- M694V/-
BD26 M 20 Hebron      18 D  Yes Yes         No         Yes            Arthritis, DVT, Epididymitis ---- Factor V Leiden 
BD27 F 29 Hebron      22 D  Yes Yes         Yes        No     ---- ---- ----
BD28 M 40 Hebron      39 D  Yes Yes         No         Yes            Arthritis, DVT,SIJ, Thrombophlebitis ---- ----
BD29 F 41 Hebron      33 P  Yes Yes         No         No            Back pain ---- ----
BD30 F 25 Hebron      20 P  Yes Yes         No         No            Arthritis, SIJ              BD sister ----
BD31 M 27 Hebron      24 P  Yes Yes         No         No     ----              BD relatives  ----
BD32 M 52 Bethlehem      50         P  Yes Yes         No         No            Subcutaneous Thrombophlebitis ---- F721/-
BD33 F 35 Abu Deis        35 P  Yes Yes         No         No            Back pain ---- ----
BD34 F 42 Bethlehem      35 P  Yes No          No         Yes            Back pain              BD sister     V726A/-
BD35 M 14 Hebron           11 P  Yes Yes         No         No                      ----              BD mother + 3 Aunts      ----
BD36 F 32 Hebron      22 P  Yes Yes         No         No            Arthralgia ---- ----
BD37 F 33 Hebron      30 P  Yes Yes         No         No            Arthritis              BD relatives E148Q/-
BD38 F 19 Hebron      18 P  Yes No          No         Yes            Arthritis, diarrhea, SIJ ---- ----
BD39 F 13 Hebron       9 P  Yes Yes         No         No            Arthritis ---- M694V/-
BD40 M 33 Jerusalem       32 P  Yes Yes         No         No            Arthritis ---- V726A/-
BD41 F 10 Hebron       9 S  Yes No          No         No            Knee pain once             Father with RAS ----
BD42 F 23 Hebron       15 S  Yes No          No         No            Arthritis, Headache             Father with RAS ----
BD43 M 10.5 Hebron       9.5 S                 Yes No          No         No            Gastrointestinal lesions ---- M694V/A744S
BD44 M 9 Hebron       8 S  Yes No          No         No                     ----  ---- V726A/-
*M: Male, F: Female, **yr: Year, §D: Definite, P: Probable, S: Suspected, †SIJ: Sacroiliac Joint Involvement, ‡DVT: Deep Venous Thrombosis, ┴CNS: Central Nervous System, ║RAS: Recurrent Aphthous 
Stomatitis.
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Table III.3 Frequency of BD manifestations in Palestinian patients
Manifestation Number of patients     Percentage 
        n = 44            (%)
Oral ulcers 44 100
Genital ulcers 37 84.1
Skin lesions 27 61.4
Eye lesions 7 15.9
Arthritis/Arhralgia 30 68.2
Vascular 5 11.4
Neuro-BD 1 2.3
Gastrointestinal 2 4.5
Epididymitis 3 6.8
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Table III.4 Predominant symptoms at presentation
Type of presentation Number of patients     Percentage (%)
Oral only 4 9.1
Oral + genital 10 22.7
Oral + skin 2 4.6
Oral + genital + skin 21 47.7
Oral + genital + eye 3 6.8
Oral + eye + skin 1 2.3
Oral + genital + skin + eye 3 6.8
Total 44 100
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Table III.5 MEFV genotypes among the Palestinian BD patients
Genotype Number of patients Percentage (%)
E148Q/—     5 11.4
V726A/— 3   6.8
M694V/— 2 4.5
M694I/— 1   2.3
F479L/— 1  2.3
V722M/— 1   2.3
F721/— 1  2.3
M694V/E148Q 1  2.3
M694V/A744S 1   2.3
E148Q/P706 1   2.3
E148Q/P369S/R408Q 1   2.3
   —/—          26           59.1
Total 44   100
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Table III.6 MEFV gene mutations among Palestinian BD patients
Mutation/ Number      Percentage 
Polymorphism of independent alleles            (%)
E148Q     8 22.2
M694V 4 11.1 
V726A 3 8.3    
M694I 1 2.8    
F479L 1 2.8     
P369S 1 2.8
R408Q 1 2.8
A744S 1 2.8
V722M 1 2.8  
P706 1 2.8
F721 1 2.8
Unidentified alleles 13 36.1
Total 36 100 
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Table III.7 Distribution of MEFV genotypes according to BD patients' 
status
Disease status* Genotypes                    Number of patients  
                                
D
E148Q/— 4
M694V/— 1
M694I/— 1
F479L/— 1
V722M/— 1
E148Q/ P706 1
M694V/ E148Q 1
E148Q/ P369S/ R408Q 1
11/28
P
V726A/— 2
M694V/— 1
E148Q/— 1
F721/— 1
5/12
S
V726A/— 1
M694V/ A744S 1
2/4
*D: Definite, P: Probable, S: Suspected
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Table III.8 Clinical severity score of BD patients
Patient' Code Clinical Severity Score MEFV Genotype
BD1 4 ---
BD2 7 ---
BD3 5 E148Q/—
BD4 8        E148Q/P706
BD5 4 ---
BD6 5 E148Q/—
BD7 5 E148Q/—
BD8 7 F479L/—
BD9 3 ---
BD10 4 ---
BD11 5 ---
BD12 5 ---
BD13 4 M694I/—
BD14 8 ---
BD15 6 ---
BD16 3 V722M/—
BD17 3 E148Q/P369S/R408Q
BD18 1      V726A/—
BD19 5 E148Q/—
BD20 5 ---
BD21 10 ---
BD22 9 ---
BD23 8       M694V/ E148Q
BD24 2 ---
BD25 2 V726A/—
BD26 2 ---
BD27 3 ---
BD28 4 E148Q/—
BD29 4 ---
BD30 4 M694V/—
BD31 4 V726A/—
BD32 12 ---
BD33 1 ---
BD34 3 ---
BD35 4       M694V/A744S
BD36 3      F721/—
BD37 4 ---
BD38 2 --- 
BD39 5 M694V/—
BD40 11 ---
BD41 3 ---
BD42 4 ---
BD43 8 ---
BD44 2 ---
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Table III.9 Comparison of various clinical manifestations between BD 
patients with and without MEFV mutations
Clinical Feature          BD With        BD Without              P
    Mutation, n =18      Mutation, n =26          Value
  n (%)   n (%)
Oral ulcers 18 (100) 26 (100) NS*
Genital ulcers 14 (77.8) 23 (88.5) NS
Eye features 2 (11.1) 5 (19.2) NS
Skin features 12 (66.7) 15 (57.7) NS
Arthritis/Arthralgia 12 (66.7) 18 (69.2) NS
Vascular 2 (11.1) 4 (15.4) NS
Neuro–BD 0 (0.0) 1 (3.9) NS
Gastrointestinal 2 (11.1) 0 (0.0) NS 
Epididymitis 0 (0.0) 3 (11.5) NS
Family history 5 (27.8) 6 (23.1) NS
Age of onset 19.4±13.1 22.2±9.6 NS
    
Disease severity 4.4±2.0 5.0±3.1 NS
*NS: Not Significant 
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Table IV.1 Frequency of MEFV mutations among BD patients in 
different studies
       
        Percentage of independent alleles
Mutation/
Polymorphism Present      Touitou Ben-Chetrit  
 study      et al., 2000 et al., 2002
n = 44          n = 57       n = 53
   
M694V 4.6 2.6        4.7
 
M694I 1.1   0.0        1.9
V726A 3.4 2.6        2.8
M680I  0.0  0.0        1.9
E148Q   9.1 5.2        5.7
L110P 0.0 2.6        ND*
F479L 1.1    ND        ND
P369S 1.1 ND        ND
R408Q 1.1 ND        ND
A744S 1.1 0.0        ND
V722M 1.1  0.0        ND
P706 1.1 10.5        ND
F721 1.1 0.0        ND
Identified alleles 26.1 23.5        17.0
Unidentified alleles 73.9 76.5        83.0
Total 100 100        100
* ND: Not Done.
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Table IV.2 Frequency of clinical findings of BD in various countries
                                                                            
Country                  Number     M/F          Mean age at onset Oral Genital Papulo- Erythema   Eye Arthritis CNS     Phlebitis  Pulmonary   GIS    Epididymitis 
                            of patients                        (Mean±SD)       aphthae  ulceration pustular nodosum    (%)         (%)     (%)    (%)      (%)      (%)     (%) 
     (%)       (%)       (%)         (%) 
    
Turkey 2147 1.03/1        38.5      100 88.2 54.2 47.6 28.9 15.9 2.2 10.6 1 2.8 -
Iran 3443 1.4/1    26.2 ± 9.6     95.8 64 65.8 22.9 57.8 39.9 3.3 6.3 0.7 - 6
Tunisia 716 3.5/1             27  98 79 62 - 51 35 31 23 1.4 4 2
Saudi Arabia 145 3.4/1        29.3 100 87 57 - 56 37 44 25 14 4 4
Iraq 60 3/1        29.4 97 83 48 55 33 48 2 17 - 10 22
Egypt 34 1.6/1    22.9 ± 5.3    100 94 29.4 20.5 41.1 61.7 14.7 5.9 0 - -
Israel 69 1.3/1           - 100 40 74 - 30 8 28 23 0 26 0
Kuwait 29 3.1/1        33.8 100 93 76 45 69 69 14 - 34 21 -
Jordan 20 2.3/1         32 100 65 35 5 65 55 5 20 5 5 5
Lebanon 100 1.3/1         26 99 78 53 25 63 65 14 11 4 10 2
Greece 70 1.9/1         24 100 78.1 93.7** - 75 48.4 20.3 7.8 1.5 4.6 10.9
Palestine*** 44 1.3/1   21.2 ± 11.2 100 84.1 59.1 11.3 15.9 50.0 2.3 11.4† 0 4.5 6.8
CNS: Central nervous system involvement; GIS: gastrointestinal system involvement; -: not defined; **skin lesions; ***present study; 
†vascular involvement [Saylan et al., 1999].
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Table IV.3 Prevalence of factor V Leiden mutation among BD patients 
in different studies
All BD       BD patients     BD patients         Controls           References      
Patients   with thrombosis   without thrombosis
   (%)   (%)           (%)  (%)
29.3    - -    5        Kosar et al., 2002
22.7    - -    7.1        Kosar et al., 2002
27.4    - -  19.2          Verity et al., 1999c
25.5     - -     -              Kosar et al., 2002
0.0    - -     2              Espinosa et al., 2002
0.0    - -    0.0           Kosar et al., 2002
23  37.5            9.4  10.3           Gül et al., 1996
19.8  30            9.2  10.6            Kosar et al., 2002
14.3  18.3           10     2              Toydemir et al., 2000
11.4  20           10.3     -              Present Study
-: Not Defined
100
             
Figure I.1 Spectrum of organ involvement in Behçet's disease [Verity et al., 
2003].
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Figure I.2 Characteristic Lesions of Behçet’s Disease.
Panel A shows multiple aphthous ulcers on the buccal membrane, gingiva, 
and labial mucosal membrane (arrows). Panel B shows an active genital 
ulcer (short arrow) and scars (long arrows) on the scrotum. Panel C shows 
hypopyon (arrow) - a horizontal layer of inflammatory cells in the anterior 
ocular chamber - and deformity of the iris. The bright circle in Panel C is 
reflected light. Panel D shows new and old lesions of erythema nodosum 
on the front of the legs [Sakane et al., 1999].
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Figure I.3 Behçet’s disease is associated with multiple hereditary and 
environmental risk factors [Verity et al., 2003].
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Figure I.4 Pyrin's identified domains and corresponding functions. 
The amino and carboxy termini are indicated by NH2 and COOH, respectively. 
The numbers above the protein segments refer to their amino acid positions on 
the primary proteins structure [Samuels et al., 1998].
PYRIN domain
Protein-protein 
interaction
1-95
30
Figure I.5 Proposed Role of Pyrin in Regulating ASC-Mediated Caspase-1 
Oligomerization
Left:  LPS  and  proinflammatory  cytokines  induce  ASC,  which  binds  pro 
caspase-1  through  cognate  CARD  interactions  and  leads  to  caspase-1 
oligomerization and autocatalysis. Active p10/p20 subunits cleave pro-IL-1β to 
mature  IL-1β,  leading  to  fever  and  inflammation.  Right:  LPS  and 
antiinflammatory cytokines induce pyrin, which binds ASC through homotypic 
PYRIN domain  interactions,  sequestering  ASC and blocking  its  interaction 
with caspase-1 [Chae et al., 2003].
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Figure I.6 MEFV Gene structure. 
The approximate location of MEFV on the subtelomeric region of chromosome 
16 followed by a schematic representation of its 10 exons. Mutations are listed 
under their respective exon, with underlined mutations representing those most 
commonly identified and one mutation in italics representing the only known 
truncation mutation [Hull et al., 2003].
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Figure II.1 The ARMS assay.
(a) normal homozygous DNA (allele 1); (b) heterozygote DNA (allele 1 and 
2); and (c) affected homozygote DNA (allele 2). In (a) only the normal allele is 
present therefore only the primer specific to allele 1 is incorporated into the 
PCR product with this substrate DNA. In (b) both alleles are present, therefore 
in their respective PCR reactions, both ARMS primers give rise to PCR 
product. In (c), with only allele 2 is present, only the allele 2 primer has a 
complementary substrate and is extended and generates amplified product. AP: 
ARMS primer; CP: common primer [Newton and Graham, 1997].
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Figure III.1 Gel electrophoresis for ARMS analysis and DNA sequence 
electropherogram of L110P mutation.
A. Agarose gel electrophoresis of amplified DNA by ARMS assay showing 
the 338 bp fragment of L110P mutation. Lanes M: DNA molecular weight 
marker, lanes 1–4: normal patient's samples, lanes 5 and 6: normal control, 
and lanes 7 and 8: blank sample. Lanes 1, 3, 5 and 7 represent the PCR 
product of the mutant primer, whereas lanes 2, 4, 6 and 8 represent the PCR 
product of the normal primer. B. DNA sequence analysis of a section of 
exon 2 in the human MEFV gene utilized by using the forward primer: 
5'CCCTAAACGTGGGACAGCTTCATC3' and the reverse primer: 
5'CCATTCTTTCTCTGCAGCCGATATAAAG3', showing the normal 
nucleotide sequence CTG at codon 110 for the normal control individual.
68
L110P
300 bp
A
B
 Figure III.2 Gel electrophoresis for ARMS analysis and DNA sequence 
electropherogram of P706 polymorphism. 
A. Agarose gel electrophoresis of amplified DNA by ARMS assay showing 
the 268 bp fragment of P706 polymorphism. Lanes M: DNA molecular 
weight marker, lanes 1–4: normal patient's samples, lanes 5 and 6: 
heterozygote patient sample, and lanes 7 and 8: blank sample. Lanes 1, 3, 5 
and 7 represent the PCR product of the mutant primer, whereas lanes 2, 4, 6 
and 8 represent the PCR product of the normal primer. B. DNA sequence 
analysis of a section of exon 10 in the human MEFV gene showing the 
normal nucleotide sequence CCG at codon 706 (left). The G→A 
substitution changes the sequence of codon 706 from CCG to CCA, but 
keeping the same amino acid "proline" (right). The downward arrow points 
to heterozygous alteration. 
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Figure III.3 DNA sequence electropherograms of F721 polymorphism 
and V722M mutation.
A. DNA sequence analysis of a section of exon 10 in the human MEFV 
gene showing the normal nucleotide sequence TTC at codon 721 and GTG 
at codon 722. B. The C→T substitution changes the sequence of codon 721 
from TTC to TTT, but keeping the same amino acid "phenylalanine" (left). 
The G→A substitution changes the sequence of codon 722 from GTG to 
ATG and results in a predicted valine-to-methionine substitution (right). 
The downward arrows point to heterozygous alteration.
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 Figure III.4 Agarose gel electrophoresis for ARMS analysis of factor V 
Leiden mutation.
Gel electrophoresis of amplified DNA by ARMS assay showing both the 
normal 233 bp and the mutant 246 bp fragments of factor V Leiden 
mutation. Lanes M: DNA molecular weight marker, lanes 1–4: normal 
patient's samples, lanes 5 and 6: heterozygote patient sample, and lanes 7 
and 8: blank sample. Lanes 1, 3, 5 and 7 represent the PCR product of the 
mutant primer, whereas lanes 2, 4, 6 and 8 represent the PCR product of the 
normal primer.
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